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Aaron Carl Willis 
USING MARION COUNTY, INDIANA CORONER RECORDS AND DEPUTY 
FIELD OFFICER REPORTS TO UNDERSTAND HEROIN AND PRESCRIPTION 
PAINKILLER OVERDOSES 
Deaths due to prescription painkillers and heroin have quickly become national, 
state, and local public health concerns.  Studies using data from Medical Examiners or 
Coroner Offices throughout the United States have been conducted and are contributing 
to the understanding of this epidemic.  However, the analysis of these fatalities are 
specific to the communities where the study was conducted and cannot be assumed that 
the decedents in one community are similar to decedents in another community.  Many 
local governments and agencies throughout the U.S. are aware that this problem exists in 
their communities, but are not prepared to adequately respond to and intervene in these 
fatalities as an analysis of those who have died has rarely been conducted.  This 
dissertation is a replication study of longitudinal epidemiological analyses of opiate-
related fatalities that was implemented in a location where an analysis of opiate-related 
fatalities had not been conducted, Marion County, Indiana.  The purpose of the 
dissertation was twofold: (1) to describe the demographic characteristics of the decedents 
using publicly available data from the Marion County Coroner’s Office to be used in 
informing future preventative efforts to decrease opiate-related fatalities in Marion 
County and (2) to inform other communities on how to conduct a similar analysis in their 
own community.   
This dissertation describes the methods of the replication study, provides 
descriptive results of the people who died from opiate-related overdoses, and:  (a) Report 
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the types of opiates identified in blood toxicology reports and (b) Present the histories of 
opiate-related decedents as reported in the Deputy Coroner Field Officer’s Reports 
(DCFOR).  Additionally, analysis was conducted to determine if decedent characteristics 
deferred depending on the type of opiate fatality based on the toxicology in 1) heroin 
alone, 2) painkillers alone, and 3) heroin and painkillers combined. 
Kathy Lay, PhD, Co-Chair 
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Chapter 1 Introduction 
Deaths due to prescription painkillers and heroin have quickly become national, 
state, and local public health concerns.  In the U.S., opiate overdose deaths have seen 
over a threefold increase from 1999 (13,995 deaths) to 2015 (48,987 deaths) (Centers for 
Disease Control and Prevention [CDC], 2016).  Indiana reported 145 deaths related to 
opiate overdoses in 1999 and 1,140 deaths in 2015, almost an eight-fold increase (CDC, 
2016).  Marion County reported 14 deaths in 1999 and 244 deaths in 2015, over a 
seventeen-fold increase (CDC, 2016).  In Table 1, the number of deaths and the crude 
death rate are displayed per 100,000 people for the US, Indiana, and Marion County for 
the years 1999 – 2015.  Figure 1 is a comparative line graph reporting the crude death 
rate per 100,000 people for the US, Indiana, and Marion County. 
Table 1: Opiate-related Fatalities: Number of Deaths and Crude Death Rate 1991-2015 
Year 
United States Indiana Marion County 
# of deaths 
Death Rate 
per 100,000 # of deaths 
Death Rate 
per 100,000 # of deaths 
Death Rate 
per 100,000 
1999 13,995 5 145 2.4 14 1.6 
2000 14,572 5.2 157 2.6 11 1.3 
2001 16,170 5.7 207 3.4 19 2.1 
2002 19,829 6.9 200 3.2 14 1.6 
2003 21,732 7.5 314 5.1 15 1.7 
2004 23,599 8.1 392 6.3 22 2.5 
2005 26,219 8.9 449 7.2 20 2.3 
2006 30,525 10.2 555 8.8 34 3.9 
2007 31,915 10.6 598 9.4 58 6.6 
2008 32,655 10.7 608 9.5 58 6.5 
2009 33,379 10.9 786 12.2 137 15.2 
2010 34,898 11.3 792 12.2 132 14.6 
2011 37,982 12.2 854 13.1 144 15.8 



























Figure 1: Opiate Related Crude Death Rate per 100,000 People 
 
Background on Prescription Painkiller and Heroin Use, Misuse, and Overdose 
The misuse of prescription painkillers is a far-reaching public health concern.  In 
2015, 12.4 million people reported illicit misuse of prescription painkillers (i.e., opiates 
and opioids) (Substance Abuse and Mental Health Services Administration [SAMHSA], 
2016).  In 2010, prescription painkillers accounted for the majority of the 5.1 million 
drug-related emergency department (ED) visits (SAMHSA, 2013).  Substance misuse 
treatment at inpatient and outpatient clinics for opiate misuse has risen from 17% of all 
types of substance misuse treatment episodes in 2000 to 28% in 2013. Opiates other than 
heroin accounted for 16% of all primary opiate admissions in 2003, but rose to 33% in 
2013 (SAMHSA, 2015).  Moreover, opiate overdose deaths have increased threefold 
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Alarmingly, these trends continue to rise as the use of prescription painkillers has 
also increased.  Retail sales of prescription painkiller medications in the U.S. increased 
149% from 1997 to 2007 and account for 80% of global painkiller consumption 
(Manchikanti, Fellows, Ailinani, & Pampati, 2010).  A proportion of the use of 
prescription painkillers may be warranted as the Institute of Medicine (2011) estimates 
100 million U.S. adults suffer from chronic pain.  The source of this pain is far-reaching 
and touches all areas and communities of the U.S.  Chronic severe pain is prevalent in 
diseases, such as cancer (Deandrea, Montanari, Moja, & Apolone, 2008), diabetes (Krein, 
Heisler, Piette, Makki, & Kerr, 2005), HIV/AIDS (Tsao, Stein, & Dobalian, 2010), 
sickle-cell disease (Elander, Lusher, Bevan, Telfer, & Burton, 2004), and gastro-intestinal 
issues (Bruce & Krukowski, 2006).  Specific populations have been identified as 
especially challenged by pain, such as children (Finley, Kristjansdottir, & Forgeron, 
2010), older adults (Reisner, 2011), people from racial and ethnic minorities (Anderson, 
Green, & Payne, 2009), military personnel and veterans (Kerns & Dobscha, 2009), and 
recently released prisoners (Andrews & Kinner, 2012; Binswanger, Blatchford, Lindsay, 
& Stern, 2011; Wakeman, Bowman, McKenzie, Jeronimo, & Rich, 2009). 
Special Population: Military Personnel and Veterans 
Prescription painkiller use among active duty U.S. military personnel and veterans 
is receiving much attention due to the increased use of prescription painkillers that are 
attributed to service-related injuries and disabilities among this population (Bennett, 
Elliott, & Golub, 2013; Goebel et al., 2011; Golub & Bennett, 2013; Morasco & 
Dobscha, 2008; Seal et al., 2012).  The Department of Defense (DoD) has been 
monitoring health-related behaviors among active duty military personnel for over three 
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decades with the use of the DoD Surveys of Health Related Behaviors Among Active 
Military Personnel and using these findings to improve policies and services for military 
personnel (Barlas, Higgins, Pflieger, & Diecker, 2013).  Indeed, beginning in 2011, the 
survey instrument was adjusted to account for current issues such as, prescription 
painkiller misuse, traumatic brain injuries, and multiple deployments (Barlas et al., 2013).  
Due to these changes, trends in prescription painkiller misuse through survey iterations is 
unable to be determined (Barlas et al., 2013).  Nonetheless, researchers are concerned 
with the increased use of prescription painkillers among military personnel and veterans 
and have begun to monitor the spreading use, misuse, and overdoses of prescription 
painkillers (Barry et al., 2011; Bennett et al, 2013; Goebel et al., 2011; Golub & Bennett, 
2013, 2014; Morasco & Dobscha, 2008; Seal et al., 2012; Wu, Lang, Hasson, Linder, & 
Clark, 2010). 
In a New York City sample of U.S. veterans of the Iraq and Afghanistan wars, 
researchers found that misuse of prescription painkillers was not present before 
deployment and that misuse began after being treated with painkillers for active duty and 
combat-related injuries.   Additionally, current and future misuses of painkillers are 
associated with a history of alcohol and drug use disorders, traumatic brain injury, 
homelessness, and unemployment (Golub & Bennett, 2013).  A qualitative study using 
the same New York City sample reported that experiences with overdoses from 
prescription painkillers are common among returning war veterans (Bennett et al., 2013).  
Seal and colleagues (2012) found that veterans with a PTSD diagnosis were at increased 
risk for being prescribed and misusing painkillers, while Goebel and associates (2011) 
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and Morasco and Dobscha (2008) both report that military personnel and veterans with 
previous substance use disorders were more likely to misuse prescription painkillers.   
Active duty military personnel self-reported use of illicit drugs, and prescription 
drug misuse increased from 5% in 2005 to 12% in 2008 (Jeffery, Babeu, Nelson, Kloc, & 
Klette, 2013), prompting the U.S. Congress to review prescription drug misuse among 
military personnel (U.S. Senate, March 24, 2010).  Furthermore, 47% of returning Iraq 
and Afghanistan soldiers report experiencing pain and discomfort and 14% of U.S. 
soldiers have been prescribed a prescription painkiller (U.S. Army, 2012).  Prescription 
painkillers were involved in 312 overdose deaths among active-duty Army Personnel 
from 2006-2011 (U.S. Army, 2012). 
Clinical and Policy Responses to Overdoses 
Clinical and policy responses aimed at addressing the misuse of prescription 
painkillers typically include opiate specific treatment centers, increased enforcement, 
implementation of prescription drug monitoring programs (PDMP) (Gugelmann & 
Perrone, 2011), and reduction in prescribing opioids (Dowell, Haegerich, & Chou, 2016).  
Although PDMPs can decrease the amount of diverted prescription drugs in the 
community, they have had limited success with decreasing use of prescription drugs and 
have little to no effect on the number of overdose mortalities (Paulozzi, Kilbourne, & 
Desai, 2011).  Additionally, despite recent reports on the decline in opiates being 
prescribed by physicians, opioid-related overdose fatality rates continue to rise (Schuchat, 
Houry, & Guy, Jr., 2017).  
To address the increasing fatality rates, an alternative approach has been 
proposed; namely, to ensure more widespread dissemination of the opiate antidote, 
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naloxone.  Naloxone is an opiate antagonist that safely and effectively reverses the often-
fatal respiratory depression effects caused by an opiate overdose (Chamberlain & Klein, 
1994; Sporer, 2003).  Naloxone only works with opiates and has no similar antidote 
properties for any other illicit or licit drug, including alcohol (Chamberlain & Klein, 
1994; Sporer, 2003) and has been clinically available since 1962 (Baselt, 2000).  
Naloxone has been routinely used by paramedics, emergency departments, and other 
medical services to reverse the otherwise fatal effects of a heroin or prescription 
painkiller overdose (Sporer, 2003; Strang, Kelleher, Best, Mayet, & Manning, 2006).  
Despite its extensive clinical history and efficacious nature, it is relatively unknown to 
the general community and has limited use due to federal and state administrative 
restrictions (Beletsky, Burris, & Kral, 2009; Burris, Norland, & Edlin, 2001; Davis, 
Webb, & Burris, 2013; Green et al., 2013).  
An overdose occurs when opiate molecules bind to opiate specific receptors, Mu2 
receptors, in the brain that are responsible for detecting carbon dioxide levels in the 
bloodstream and controlling the channel of communication needed for breathing.  As 
opiate molecules begin to attach to Mu2 receptors, the breathing rate decreases and 
breaths of air become shallower.  Eventually, as more opiate molecules bind to Mu2 
receptors, the communication between the brain and lungs stops, thus leading to 
respiratory failure, and if no intervention, then death (Sporer, 1999; White & Irvine, 
1999).  When naloxone is introduced into the body, it causes the opiate molecules to 
release from the Mu2 receptors almost immediately and communication between the 
brain and lungs is restored, allowing the body to breathe.     
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Therefore, naloxone has the potential to save individuals’ lives quickly.  Despite 
having no euphoric properties or potential for abuse or overdose (Chamberlain & Klein, 
1994; Sporer, 2003), naloxone is a controlled substance that must be prescribed by a 
physician, typically limiting immediate access to emergency responders and EDs (Burris 
et al., 2009).  These restrictions greatly limit individual access to naloxone, which can 
result in otherwise avoidable deaths (Zador, Sunjic, & Darke, 1996).  The process from 
overdose to death can take several hours, but irreversible brain damage may result if 
someone is revived only after long periods of slow and shallow breathing (O’Brien & 
Todd, 2009).  In many cases, death occurs before emergency responders can respond 
(Sanford, 2004).   
Because of these limitations in access to naloxone, some researchers 
recommended that naloxone be readily available to those who use opiates and to their 
family members and friends (Darke, Ross, & Hall, 1996; Lagu, Anderson, & Stein, 2006; 
Sporer, 1999; Strang, Darke, Hall, Farrell, & Ali, 1996).  Though emergency response 
services are readily available in most cases of an overdose, Tobin and colleagues (2005) 
found that slow response times by emergency responders is not the only reason for 
overdose fatalities, but that bystanders of opiate overdoses are unlikely to call 911 for 
assistance due to fear of legal repercussions.  Many people who misuse opiates are on 
parole or have outstanding warrants (Davidson, et al., 2003).  Research has established 
that bystanders witnessing an opiate overdose would be willing to, and have successfully 
administered, naloxone to victims of opiate overdoses (Baca & Grant, 2007; Doe-
Simkins, Walley, Epstein, & Moyer, 2009; Green, Heimer, & Grau, 2008; Lagu et al., 
2006; Strang et al., 1999; Walley et al., 2013).   
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Despite the findings reported above, naloxone is still not widely available in the 
U.S.  Indeed, only 136 programs in a total of 30 states currently distribute naloxone 
through community-based programs, such as needle exchange programs (CDC, 2015).  
At these programs, naloxone is distributed directly to their clients, after a brief 10-to 30-
minute training (Albert et al., 2011; Green at al., 2008; Piper at al., 2007).   These 
programs are typically in areas with high concentrations of intravenous drug use (IDU) 
and HIV/AIDS, thus generating the political and societal support for needle exchanges 
and other HIV/AIDS and IDU community-based interventions.  However, national 
epidemiological drug use studies have clearly established that opiate misuse and overdose 
is not limited to these thirty states (Johnston, O’Malley, Miech, Bachman, & 
Schulenberg, 2017; SAMHSA, 2016).  The challenge facing the other twenty states is 
how to distribute naloxone effectively to those in greatest need, without the foundational 
support of needle exchange programs and other similar community-based efforts. 
Current state of U.S. naloxone distribution 
Distribution programs.   
The distribution of naloxone is a relatively new concept.  In 1999, underground 
operations in Chicago and San Francisco began distributing naloxone to active IDUs with 
the hope that they would be able to prevent potential overdose fatalities (Sporer & Kral, 
2007).  A physician would prescribe naloxone and train active IDUs in the proper 
administration of the drug.  However, this arrangement put the prescribing physician at 
risk for civil, medical, and legal liability mainly in that naloxone would either not be 
administered by the individual for whom the drug was prescribed or that the prescribed 
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naloxone would be injected into an individual who did not have a prescription for that 
drug.   
In 2001, after becoming aware of the successes these underground operations 
were having with decreased overdose fatalities through distributing naloxone, the San 
Francisco Department of Public Health funded a pilot naloxone distribution program 
(Seal et al., 2005).  In this program, 24 IDUs enrolled in the program, which was 
modeled after the two underground operations. Enrollees attended four 2-hour interactive 
training sessions where they learned how to identify an overdose, administer CPR, 
contact emergency medical services, and administer naloxone.  Upon successful 
completion of the program, each person was provided a naloxone kit that contained two 
prefilled injection cartridges of naloxone, gloves, a rescue-breathing mask, and detailed 
instructions.  Additionally, a written prescription for naloxone was provided to each 
participant.  From August 2001 through January 2002, the participants reported 
witnessing and responding to 20 overdoses and all victims survived (Seal et al., 2005). 
Also in 2001, New Mexico became the first state to recommend that physicians 
prescribe naloxone to active opiate users.  The then New Mexico Governor, Gary 
Johnson, was the leader of the legislation that released the medical liability of individuals 
and medical professionals who administered naloxone (Sporer & Kral, 2007).  
Connecticut and New York shortly followed New Mexico by granting all individuals 
immunity from civil and medical liability for administering naloxone by defining the use 
of naloxone as a first aid or emergency treatment (Beletsky, Burris, & Kral, 2009).  
Currently, eight states (NY, IL, WA, CA, RI, CT, MA, and NM) have made legal 
changes to remove medical, legal, and civil liability concerning the administration of 
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naloxone (Davis, Webb, & Burris, 2013).  Throughout the U.S., an estimated 644 
community agencies provide education and training, similar to the training described 
above, to potential opiate overdose bystanders (i.e., family members, friends, community 
advocates, active opiate users) in order to distribute and administer naloxone to potential 
overdose victims.  Moreover, these agencies have trained over 150,000 potential 
bystanders that have prevented over 26,000 opiate overdose fatalities with the use of 
naloxone (CDC, 2015).   
Recently, several state legislatures, including Indiana, have revised naloxone 
administration laws and regulations allowing all first responders and third parties (i.e., 
family member or friends) to administer naloxone.  Indiana’s law, specifically, allows 
physicians to administer prescriptions to third parties or people who misuse heroin and 
opiates.  Additionally, the law grants immunity from civil and medical liability 
(Muraskin, 2015). 
Future directions.   
Despite the successes described above, there is still much to be done to ensure 
access to naloxone throughout the U.S.  The strong push to increase naloxone access is 
coming from multiple fronts (legal, medical, and policy scholars) focusing on three 
targeted areas.  The first targeted area is to increase the number of physicians who are 
prescribing naloxone.  Primary care physicians and other physicians who have more 
frequent contact with active opiate users, such as ED physicians, are encouraged to 
provide naloxone prescriptions to their patients who are active opiate users (Beletsky et 
al., 2006; Kim, Irwin, & Khoshnood, 2009; Sporer & Kral, 2007).  Additionally, chronic 
pain physicians and other physicians who work closely with people with painful chronic 
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illnesses, such as cancer, are also being asked to provide naloxone prescriptions, due to 
the increased risk of chronic pain patients misusing their prescription painkillers 
(Beletsky et al., 2009; Beletsky, Rich, & Walley, 2012).  Unintentional overdoses are 
more likely to involve prescribed medication than illicit drugs (CDC, 2012).   
The second targeted area is to advocate for changes in state laws and regulations 
that restrict the availability of naloxone.  As described above, only eight states have taken 
direct measures to address the legal, civil, and medical liability that may follow 
administering naloxone.  Some states have passed laws that allow other licensed medical 
professionals (i.e., nurse practitioners, physician assistants) to prescribe naloxone, instead 
of only a physician (Beletsky et al, 2009; Burris et al., 2009).   
Finally, the third targeted area involves the Food and Drug Administration (FDA) 
reclassifying naloxone from prescription-only to an over-the-counter (OTC) drug.   This 
process is likely to be lengthy, cumbersome, and expensive, due to all of the paperwork 
and filings required of pharmaceutical companies.  However, support is strong for this 
option  as the best way to make naloxone readily available  (Beletsky et al., 2009; Burris 
et al., 2009; Coffin et al., 2003; Compton, Volkow, Throckmorton, & Lurie, 2013; Kim et 
al., 2009; Lagu et al., 2006; Seal et al., 2003; Sporer & Kral, 2007). 
Conceptualization of the Problem 
 The foundation of this dissertation research rests on preventing opiate-related 
overdose fatalities.  Naloxone is clearly the most effective tool for preventing acute 
overdose fatalities.  As stated above, increasing the availability and reach of naloxone is a 
complex endeavor with numerous barriers, including policies at all levels of government, 
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professional regulations, and probably most damaging, public stigma surrounding 
addiction and drug misuse (Selin, Hakkarainen, Partanen, Tammi, & Tigerstedt, 2013).   
 Addressing this stigma concerning substance misuse is an important and constant 
effort that should continue; however, as opiate overdoses continue to rise so do opiate 
fatalities.  Thus, it is prudent and ethical to seek alternative channels of using naloxone 
for preventing and intervening in opiate overdoses.  This dissertation research involves a 
longitudinal, epidemiological analyses of opiate-related fatalities. It was implemented in 
a location where an analysis of opiate-related fatalities had not previously been 
conducted, Marion County, Indiana.  The purpose of the study was to describe the 
demographic characteristics of the decedents using information from death certificates, 
toxicology reports, and the death investigation and then apply this information to inform 
future preventative efforts to decrease opiate-related fatalities. 
  Further exploration is needed concerning overdose deaths involving chronic pain 
and chronic diseases or illnesses.   Research has not identified if one specific form of 
chronic pain (i.e., neurological, back pain) or chronic disease or illness (i.e., cancer, 
HIV/AIDS, diabetes) has a stronger positive relationship with prescription painkiller 
overdoses than others.  This information could be important, as health care providers who 
work with patients with identified higher risk conditions could be trained to place a 
greater emphasis on informing their patients about the risks of overdose from prescription 
painkillers, as well as encouraging them to prescribe naloxone to their patients.  Along 
the same line of identifying a specific illness or disease, we also do not know if specific 
populations are at risk for prescription painkiller overdoses (i.e., children, older adults, 
people from racially and ethnically diverse backgrounds).   
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Similar focus on specific overdose fatalities could also be used with specific 
populations and subcultures at risk for heroin or prescription painkiller overdoses, such as 
college students, military personnel and veterans, and individuals recently released from 
jail or prison (Andrews & Kinner, 2012; Binswanger et al., 2011; Kerns & Dobscha, 
2009; Wakeman et al.,, 2009).  Some research demonstrates that although these 
populations are at risk for overdoses, specific risk profiles from within these populations 
have not been identified.   
Perhaps, the largest gap in the literature may be the identification of the best way 
to distribute naloxone in states and cities that do not have, or do not have the need for, 
needle exchange programs.  Part of the problem with using needle exchange programs as 
a model for distribution is twofold.  First, if a large HIV/AIDS concern does not exist in a 
city or state, or it has been determined that the HIV/AIDS population in a city or state 
largely acquired their infection through channels other than needle sharing, needle 
exchange programs would have little practical value.  The second problem with using a 
needle exchange program model for the prevention of prescription painkiller overdoses 
assumes that people who use and misuse prescription painkillers behave and have a 
similar social network as those who use and misuse heroin.  Currently, data do not 
suggest that users and misusers of heroin behave and share social networks with users 
and misusers of prescription painkillers, nor is there research that describes the behaviors 
and social network of users and misusers of prescription painkillers. 
 This dissertation research is based on the collection of primary data from existing 
public records in the Marion County Coroner’s Office.  Data were collected from seven 
years of coroner’s data from 2007 through 2014.  All cases had a death certificate that 
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contained standard demographic variables and identifiable information that can be used 
to cross-reference with variables from other datasets (i.e., prescription drug monitoring 
programs; department of corrections).  Additionally, the death certificates included 
county and state of residence, cause, reason, and place of death, highest education 
achieved, and former military status.  The decedent case files also contain the Field 
Deputy’s and autopsy report.  The Field Deputy’s report is a detailed narrative of the 
circumstances of the death and social, medical, and general history of the deceased as 
provided by family members and police and medical records.  This report included 
information about previous injuries, surgeries, illnesses, or diseases, along with histories 
of mental health, substance use and misuse, previous overdoses, suicide attempts, and 
recent incarcerations.  The autopsy report contains a detailed toxicology report of both 
blood and urine samples that differentiates between brand of prescription painkillers, 





Chapter 2 Opiate-Related Fatalities Study Protocol: Study of Longitudinal 
Epidemiological Analyses, Marion County, Indiana 
Background 
Overdose fatalities related to the increased use and misuse of prescription 
painkillers and heroin has reached epidemic proportions in the United States (Centers for 
Disease Control and Prevention [CDC], 2012).  In 2015, 12.4 million people reported 
illicit misuse of prescription painkillers (i.e., opiates and opioids) (Substance Abuse and 
Mental Health Services Administration [SAMHSA], 2016).  In 2010, prescription 
painkillers accounted for the majority of the 5.1 million drug-related emergency 
department (ED) visits (SAMHSA, 2013).  Substance misuse treatment at inpatient and 
outpatient clinics for opiate misuse has risen from 17% of all types of substance misuse 
treatment episodes in 2000 to 28% in 2013. Opiates other than heroin accounted for 16% 
of all primary opiate admissions in 2003, but rose to 33% in 2013 (SAMHSA, 2015).  
Moreover, opiate overdose deaths have increased threefold from 1999 (13,995 deaths) to 
2015 (48,987 deaths) (CDC, 2016).  States have monitored these fatalities, providing 
necessary information that has contributed to the understanding of opiate overdose 
fatalities (Cerda et al., 2013; Green, Grau, Carver, Kinzly, & Heimer, 2011; Johnson et 
al., 2012; Paulozzi & Xi, 2008; Piercefield, Archer, Kemp, & Mallonee, 2010; Shah, 
Lathrop, Reichard, & Landen, 2007).  As the problem has grown, it is becoming more 
apparent that this epidemic is not isolated to specific regions of the US or even specific 
populations.  Instead this epidemic is far-reaching, impacting the lives of all Americans 
(Johnston, O’Malley, Miech, Bachman, & Schulenberg, 2017; SAMHSA, 2016). 
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Surveillance of public health records, mainly death certificates, from Coroner and 
Medical Examiners’ offices were used to examine the emergence of this developing 
epidemic.  New Mexico (Mueller, Shah, & Landen, 2006; Shah et al., 2007) and Chicago 
(Scott, Thomas, Pollack, & Ray, 2007) were some of the early documenters of this crisis.  
In New Mexico, researchers examined the medical examiner records from the New 
Mexico Office of the Medical Investigator and identified all cases of an unintentional 
drug overdose death caused by an identifiable drug from 1994 – 2003.  From these 
records, they gathered toxicology reports, as well as decedent characteristics – age, 
gender, race, co-intoxication with alcohol, and urbanization level of the decedent’s 
residence.  They reported rates and trends of overdose fatalities due to prescription drugs, 
analyzed decedent characteristics, and described common drug combinations causing 
death.  Their report indicated a significant increase in rates of prescription drug overdose 
during the 10-year study period (Mueller et al., 2006).  
For Chicago’s analysis, death certificates from 1999 – 2003 were manually 
screened to identify all opiate-related fatalities and the location of the fatality, as they 
were conducting a spatial pattern analysis.  During data collection, they identified 
inconsistencies in how the medical examiner’s office filed and coded death certificates.  
The example they provided was a multiple drug combination being the cause of death, 
but the death certificate did not reveal the specific drugs involved.  This finding led the 
research group to develop a case definition for opiate-related fatalities that they detailed 
in their methods description (Scott et al., 2007). 
Johnson and colleagues (2012) interviewed decedent’s next of kin or best contact 
for opiate-related fatalities in Utah from 2008-2009.  Their purpose was to obtain more 
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in-depth information about those who died from opiate-related overdoses.  The interviews 
explored histories of chronic pain, financial problems, mental health, substance misuse, 
and patterns of pain medication use.  Using records from the Office of the Medical 
Examiner, all suspected or possible opiate-related drug overdose fatalities were included 
as candidates for interviewing.   
This study involves a longitudinal epidemiological analyses of opiate-related 
fatalities and was implemented in Marion County, Indiana, where an analysis of opiate-
related fatalities had not been conducted.  The goals of the study were to (1) describe the 
demographic characteristics of the decedents using information from death certificates, 
toxicology reports, and the death investigation and (2) use this information to inform 
future preventative efforts to decrease opiate-related fatalities.   
 For this study, data were collected using an epidemiological research design with 
existing public records. This design included a unique protocol for examining these 
records in order to understand better the magnitude of this epidemic in Marion County, 
Indiana. Over 90% of Marion County’s population lives in the city of Indianapolis, which 
is the capital of the state.  This information is presented with the hope that other cities and 
locales will replicate this protocol in order to tailor prevention and intervention strategies 
specific to their unique populations. 
Methods 
Research design and sample. 
 This study was a population-based, observational study using public records from 
Marion County, Indiana, namely coroner records and a prescription drug-monitoring 
program from the years 2007 through 2014.  Subjects for the study were identified from 
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records in the Marion County Coroner’s Office (MCCO).  Indiana’s medical death 
investigation system is county-based and conducted by an elected coroner.  State statute 
requires the Coroner to investigate all deaths from violence, casualty, apparently in good 
health, apparently suspicious, unusual, or unnatural in manner, or been found dead (Ind. 
Code Ann. §36-2-14-6).  All records were reviewed manually to identify the cause of 
death (COD) by focusing on the manner of death (MOD) determined as accident, 
undetermined, or suicide.  All case subjects were deceased.  Toxicology reports were 
used to confirm that each death was caused by an opiate or an opiate contributed in the 
death of the individual.  The Indiana University IRB was notified of this study and the 
determination was made that no IRB oversight was needed as there were no live human 
subjects in this research study.  Even though sensitive and confidential information were 
available from the death certificates, the IRB concluded that these documents are public 
records and privacy is protected by the MCCO.  The Chief Deputy Coroner is responsible 
for the release of this information and granted the researcher access to the records. 
Study procedures. 
Case study identification. 
 For each year of analysis, coroner records were searched by manner of death – 
Accident, Undetermined, and Suicide.  The Marion County Coroner uses these identifiers 
for any opiate-related mortality.  Homicide, though a possible manner of death for an 
opiate overdose, was not used as a search criterion because the Chief Deputy Coroner 
cannot ever recall an opiate overdose identified as the cause of death for a Homicide (A. 
T. Ballew, personal communication, May 8, 2014).   
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An initial search identified all of the past year decedents in Marion County whose 
manner of death was either ruled an accident, undetermined, or a suicide by the MCCO.  
For each year of the study, a Coroner employee accessed the Coroner database to identify 
all of the deaths that were ruled as an Accident, Undetermined, and Suicide.  A list was 
then generated of all of these cases.  The list was printed and then given to the 
investigator.  The list provided four columns of information – Coroner Case #, Age, Sex, 
and Race of the decedents. 
 From this list, the investigator either entered in each Coroner Case number in the 
Coroner database or manually pulled the paper file held in the Coroner’s storage area.  
The MCCO is in the process of entering all of their data electronically and some of their 
older cases (i.e., 2007-2010) have yet to be entered into their electronic database.  
Whether accessed electronically or manually, the first information gathered was from the 
Death Certificate to determine the cause of death.  The cause of death is determined by 
the pathologist who performed the autopsy and specific criteria for stating the cause of 
death do not exist.  For example, someone who has died from a heroin overdose, the 
cause of death could be Heroin Intoxication, Drug Overdose, or Opiate Intoxication.  
Similarly, if someone died from an Oxycodone and Xanax (benzodiazepine) overdose, 
the cause of death could be Mixed Drug Overdose, Opioid and Benzodiazepine 
Intoxication, Oxycodone and Alprazolam (generic name for Xanax), or Poly Drug 
Intoxication.  Thus, if any cause of death included the word heroin, painkiller, opiate, 
opioid, or any of the prescription painkiller names (e.g., Morphine, Codeine, 
Hydrocodone) then the case was included in the study. 
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 For the coroner records that did not have an opiate mentioned in the cause of 
death, toxicology reports were examined to determine if any cases were eligible for 
inclusion in the study.  Any coroner case record that had a positive test for any opiate or 
opioid found in the blood or urine sample was included in the case study.  For those 
coroner case records that did not have a toxicology report, further investigations were 
conducted with the coroner case file.  The coroner case files could include records from 
the EMTs if the decedent was transported by an ambulance to a hospital as well as any 
hospital records and insurance information.  Hospital records can contain records from 
emergency and inpatient departments.  Where appropriate, these records were examined 
to catalogue any positive identification for any opiate or opioid substance in the patient’s 
system upon admission to the emergency department or hospital.   
Data Sources. 
Marion County Coroner’s Office. 
 Data from MCCO were gathered from four potential sources: (1) Death 
Certificate (DC), (2) Deputy Coroner Field Officer Report (DCFOR), (3) Autopsy Report 
(AR), and (4) hospital records.  For every death that is reported to and examined by 
MCCO, the record will include a DC, DFOR, and AR.  If an overdose fatality involves 
the services of an ambulance or hospital, those records are forwarded and included in the 
decedent’s coroner records.  For some cases, when a drug overdose fatality occurred at a 
hospital and the MCCO is not notified to investigate the death for a variety of reasons 
(e.g., hospital administrative error; hospital doctor inadvertently signing the DC).  When 
this happens, these deaths are treated as natural deaths and do not undergo a Coroner 
investigation.  The actual number of these cases are unknown, but the Indiana State 
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Department of Health processes all death certificates that have been issued in Indiana.  
For some occurrences, the State processes these death certificates but does not identify 
the overdose fatalities that should have been investigated by MCCO.  The State then 
notifies MCCO about these fatalities and a Deputy Coroner Field Officer will conduct an 
investigation.  These type of cases are referred to as “Greensheets” and will not have an 
autopsy or toxicology performed as the body has already been buried, cremated, or 
processed in some other manner.  Greensheet cases can still be used as cases in this study, 
because hospital records are reviewed for toxicology tests administered by the hospital 
and any other information that can be used to confirm a fatality from a heroin or 
prescription painkiller overdose.  Additionally, the Deputy Coroner Field Officer will 
conduct an investigation and interview surviving family members and friends about the 
decedent’s history and events that occurred on the decedent’s date of death. 
Death certificate.   
 From the death certificate, the following information was collected by MCCO and 
Indiana State Department of Health officials about the decedent: (1) first, middle, last 
name, and maiden name; (2) sex; race; ethnicity; (3) time and date of death;  (4) date of 
birth and birth place; (5) social security number; (6) age; (7) marital status; (8) city, 
county, state, and zip code of residence; (9) city, county, state, and zip code of place of 
death; (10) surviving spouse’s name; (11) highest level of education attained; (12) 
decedent’s occupation and kind of business or industry; (13) veteran status; (14) father 
and mother’s name of decedent; (15) method and place of disposition;  (16) cause of 
death; place of death; and manner of death. 
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Deputy coroner field officer report (DCFOR). 
 The DCFOR is a narrative report detailing the events involving the overdose 
fatality.  The narrative describes the scene where the body is found, how the body is 
found (e.g., face-down, sitting in a chair), and any unique or extraordinary characteristics 
of or on the body (e.g., found naked, syringes, artifacts from emergency resuscitative 
efforts).  The narrative attempts to detail the last 24-48 hours preceding the death.  This 
information is gathered from the police and paramedics on the scene, witnesses, 
neighbors, and friends and family.  The report also attempts to document any significant 
medical or social history.  These data are gathered from multiple sources (i.e., family, 
friends, police records, hospital records) and can take several days to complete.  Seven 
descriptive variables were gathered from the medical and social history report used for 
analysis in this project:  (1) history of acute or chronic pain; (2) mental health history; (3) 
substance misuse history; (4) IDU history; (5) previous overdose; (6) previous suicide 
attempt; and (7) recent release from incarceration or an inpatient setting.  All seven 
variables were coded as occurring or not occurring.  The information gathered for three 
variables from the field deputies – history of injury, surgery, disease, or chronic disorder 
causing acute or chronic pain; history of mental health, and history of substance use – 
allow for a more detailed examination and will be described in the Measures section. 
Autopsy report.  
 An autopsy consists of two procedures: an external exam and a full exam.  In an 
external exam a general description of the body is made.  Height and weight are recorded, 
as well as identifying features, such as, race, sex, hair color and length, eye color, and 
marks on the body (i.e., scars, tattoos, birthmarks).  A medical examiner is able to 
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differentiate between a scar that was made by a medical incision or any other method.  A 
full autopsy includes an external and internal exam.  In the autopsy report, the medical 
examiner will note any surgically absent organs (i.e., spleen, ovaries, appendix), medical 
procedures (i.e., pacemaker, staples and meshing from gastric bypass, metal plates), or 
internal injuries.  
Toxicology report. 
 The MCCO routinely screens all suspicious deaths for licit and illicit drugs, 
including narcotics (e.g., heroin and opioid analgesics), stimulants (e.g., amphetamines 
and cocaine), marijuana, alcohol, depressants (e.g., benzodiazepines and barbiturates), 
and other licit drugs (e.g., antidepressants, antipsychotics, antihistamines).  Screening 
tests use blood from subclavian, iliac, or femoral sites and in unusual cases from liver 
tissue or vitreous fluid. 
Prescription drug monitoring program. 
 Indiana’s prescription monitoring program (PDMP) is called INSPECT (Indiana 
Scheduled Prescription Electronic Collection & Tracking) and is monitored and managed 
by the Indiana Professional Licensing Agency and the Indiana Board of Pharmacy.  All 
requests for de-identified data are approved or denied through the Indiana Board of 
Pharmacy and must include an INSPECT protocol and IRB application and approval for 
Indiana Board of Pharmacy review.  Additionally, a personal appearance before the 
Board may be requested. 
 The request made for this project was a bit unorthodox, as there was no IRB 
approval or monitoring of this study and the data were requested to be identifiable so the 
INSPECT data could be matched with MCCO data.  The investigators, in addition to 
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completing and submitting the INSPECT Protocol of Release of De-Identified Data, 
provided the Board with an IRB form notifying the investigator that the proposed study 
did not meet standards for IRB monitoring as there were no human subjects in the study.  
In addition to submitting the Protocol request, the investigator gave a ten-minute in-
person presentation of the request for data for the Board members.  Approval for 
INSPECT data was granted. 
 The investigator provided the INSPECT data manager with the full name, gender, 
date of birth, zip code of residence, and social security number of the decedents.  The 
INSPECT data manager then matched their records with the sources of information from 
the Coroner records.  The information provided by INSPECT include the prescribing 
practitioner (unique identifier created by INSPECT), prescribing practitioner’s zip code, 
pharmacy (unique identifier created by INSPECT), pharmacy’s zip code, prescription 
number, date prescription written, date prescription filled, the National Drug Code 




 Personal information from the deceased’s death certificate were collected in order 
to match MCCO records with INSPECT data, as well as potential future sources (e.g., 
Medicaid, Department of Corrections).  First, middle, and last names, date of birth, and 
social security numbers were collected and used only for matching purposes.  Matching 
data were not used in project analysis. 
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Demographic and Descriptive Variables. 
 Demographic variables – gender, race, ethnicity, age, residence (city, state, 
county, and zip code), highest level of education, and veteran status – were collected 
from the Death Certificate.  Additionally, the cause of death, place of death, and manner 
of death were collected from the death certificate. 
 Gender was identified as “Female” or “Male”.  Race was identified as “White”, 
“Black”, “Latino/Latina”, “Native American”, “Asian/Asian American”, or “Other”.  
Ethnicity was identified as “Not Hispanic” or “Hispanic”.  City, state, and county, and zip 
code were recorded as documented in the death certificate.  Veteran status was identified 
as “No” or “Yes”. 
Education was assigned an ordinal variable consisting of eight items – 8th grade or 
less, some high school, high school diploma/GED, some college/trade school, 
associates/trade degree, bachelor’s degree, master’s degree, and doctorate degree. 
Injury, surgery, or other potential pain causing condition. 
 The injury, surgery, or other potential pain causing condition (ISPC) was assigned 
as a dichotomous variable and measured as either having an ISPC or not having an ISPC.  
A list of all ISPCs is provided in Appendix A.   
Mental health. 
 The mental health variable was assigned as dichotomous and measured as either 
having a mental health history or not having a mental health history.  A decedent was 
identified as having a mental health history if a mental illness was reported in the DFOR, 
autopsy report, or medical records.  See Table 2 for a list and frequencies of mentioned 
mental health disorders. 
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 A history of substance misuse was assigned a dichotomous variable and measured 
as either having a history or no history of substance misuse.  See Table 3 for a list and 
frequencies of mentioned substances of misuse.  
Table 3: Frequency of Reported History of Substance Misuse: (n = 1174) 
Substance Misuse History Frequency 
Prescription medicine 540 
Alcohol 428 
Heroin 391 






Injection drug use. 
 A history of IDU was assigned a dichotomous variable and measured as either 
having a history or no history of IDU.    
Previous overdoses. 
 A history of previous overdoses was assigned a dichotomous variable and 
measured as either having a history or no history of overdoses.    
Previous suicide attempts. 
 A history of previous suicide attempts was assigned a dichotomous variable and 
measured as either having a history or no history of suicide attempts.    
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Recent release from incarceration or inpatient setting. 
A recent release from incarceration or inpatient setting was defined as occurring 
within the past two weeks.  This factor was dichotomized as either having a recent release 
from incarceration or inpatient setting or no recent release from incarceration or inpatient 
setting.   
Toxicology Reports. 
 All potential licit and illicit substances identifiable by the MCCO toxicology 
reports were each created as a variable.  All licit or illicit substances were measured and 
assigned a dichotomous variable as either appearing or not appearing in each decedent’s 
toxicology report.  See Appendix B for a list of screened licit and illicit substances. 
Data Analysis 
 All data were analyzed using SPSS 22.0 (IBM, Armonk, NY) and consisted of 
two components.  This first analysis was an exploratory descriptive analysis that involved 
determination of frequencies and percentages for key demographics such as, gender, race, 
Marion County residency, veteran status, and highest level of education.  Additionally, 
frequencies and percentages were reported for type of opiate found in blood toxicology 
reports and past significant histories as described in the DCFOR; e.g., an injury, disease, 
disorder, or surgery causing acute or chronic pain; a mental health history; a substance 
misuse history; IDU history; overdose history; suicide history; recent release from 
incarceration or inpatient setting.   
The second component was a predictive model exploring the characteristics of 
decedents with only heroin, only painkillers, or a combination of heroin and painkillers in 
their toxicology reports.  A stepwise, likelihood ratio, multinomial logistic regression 
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analysis was conducted to estimate a regression model to predict the probability of 
opiate-related overdose decedents having only heroin, only painkillers, or a combination 
of heroin and painkillers in their toxicology reports.  Prior to conducting the analysis, chi-
square and independent t-tests were utilized to examine the bivariate relationship between 
the three groups of opiate-related overdose decedents and each factor.  Each of the 
independent variables (i.e., gender, mental health history, cocaine use) were entered 
individually into a single multinomial logistic regression, twice, to identify significant 
relationships.  A multinomial logistic regression analysis was run twice to allow each of 
the dependent variables to be compared to one another, as a multinomial logistic 
regression analysis will hold one of the dependent variables as the referent group.  
Statistically significant bivariate relationships at the p ≤ 0.05 level were entered into the 
initial multinomial logistic regression.  In all, 16 factors were found to be statistically 
significant and thus were entered into the initial multinomial logistic regression analysis: 
Gender, Race, Age, Education, Marion County Residency, Socioeconomic Status 
Indicator, Acute/Chronic Pain History, Mental Health History, Substance Misuse History, 
Injection Drug Use History, Overdose History, Suicide History, Incarceration History, 
Benzodiazepine, Cocaine, and Alcohol. 
 The initial multinomial logistic regression analysis found statistically significant 
relationships (at the p ≤ 0.05 level) between the three groups of opiate-related overdose 
decedents and ten factors: gender, race, acute/chronic pain history, mental health history, 
substance misuse history, injection drug use history, incarceration history, 
benzodiazepine, cocaine, and alcohol.  On the other hand, no significant relationships 
were detected between the three groups of opiate-related overdose decedents and age, 
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socioeconomic status, education, Indianapolis residency, overdose history, and suicide 
history.  Consequently, these six factors were excluded from the final predictive model.   
Descriptive Results 
 From 2007-2014, a total of 1185 opiate-related overdose fatalities were reported 
in Marion County.  Eleven of these cases only had a death certificate and did not have a 
DCFOR and/or a toxicology report and were thus excluded from analysis.  Accordingly, 
this analysis was of coroner records of 1174 decedents.   
 Demographic data for all 1174 overdose-related deaths in Marion County are 
presented in Table 4 by year from 2007 through 2014.  The overall average age of the 
decedents was 39.7 years old.  The average age range between the study years was the 
youngest at 36.7 years old for 2007 and the oldest average age at 41.9 years old for 2009. 
Data in Table 4 also indicate that opiate-related overdoses were likely to be male 
(63.6%), White (85.6%), and a Marion County resident (82.5%).   
When examining these demographic variables over time, the number of deaths 
increased while the percentages of each variable showed little change.  For example, 
males represented about two out of every three deaths each year, which is rather 
consistent.  For years 2007 and 2011 respectively, the percentages of male deaths were 
56% and 58%, which still means at no time were females dying at a greater rate than 
males.  A similar trend with limited variability is seen with race and Marion County 







Table 4: Demographic Characteristics Overdose-Related Deaths in Marion County 
 2007 2008 2009 2010 2011 2012 2013 2014 Total 
 n=84 n=122 n=130 n=123 n=137 n=160 n=178 n=240 N=1174 
Age, mean (sd) 36.69 (12.73) 38.26 (12.13) 41.88 (11.91) 39.97 (12.59) 40.34 (11.85) 40.19 (12.26) 39.98 (12.89) 39.20 (12.08) 39.69 (12.32) 
  min-max 16-66 18-73 19-69 18-76 18-66 16-68 18-81 17-70 16-81 
Gender          
  Male, % (n) 56 (47) 66.4 (81) 65.4 (85) 61 (75) 57.7 (79) 64.4 (103) 62.9 (112) 68.8 (165) 63.6 (747) 
Race          
  White, % (n) 86.9 (73) 82 (100) 81.5 (106) 87.8 (108) 89.1 (122) 83.8 (134) 84.3 (150) 88.3 (212) 85.6 (1005) 
  African American, % (n) 11.9 (10) 17.2 (21) 16.9 (22) 11.4 (14) 7.3 (10) 15.6 (25) 12.9 (23) 10 (24) 12.7 (149) 
  Latino/a, % (n) --- 0.8 (1) 0.8 (1) 0.8 (1) 0.7 (1) 0.6 (1) 1.1 (2) 0.8 (2) 0.8 (9) 
  Asian American, % (n) --- --- --- --- 2.2 (3) --- 1.1 (2) 0.4 (1) 0.5 (6) 
  Native American, % (n) 1.2 (1) --- 0.8 (1) --- 0.7 (1) --- --- 0.4 (1) 0.3 (4) 
  Other, % (n) --- --- --- --- --- --- 0.6 (1) --- 0.1 (1) 
Marion County Resident          
  Yes, % (n) 82.1 (69) 88.5 (108) 83.8 (109) 82.1 (101) 81.8 (112) 82.5 (132) 82 (146) 80 (192) 82.5 (969) 
Indiana Resident          
  Yes, % (n) 97.6 (82) 99.2 (121) 98.5 (128) 98.4 (121) 94.9 (130) 98.1 (157) 98.3 (175) 96.3 (231) 97.5 (1145) 
Veteran          
  Yes, % (n) 7.2 (6) 9 (11) 10.2 (13) 9 (11) 9.6 (13) 5.7 (9) 9.7 (17) 8.4 (20) 8.6 (100) 
Education          
  Some HS, % (n) 28 (23) 26.2 (32) 28.5 (37) 23.8 (29) 21.8 (29) 25.6 (41) 23.2 (41) 20.5 (49) 24.1 (281) 
  HS diploma/GED, % (n) 45.1 (37) 51.6 (63) 46.9 (61) 54.1 (66) 51.9 (69) 44.4 (71) 45.8 (81) 47.3 (113) 48.2 (561) 
  Some college, % (n) 19.5 (16) 11.5 (14) 12.3 (16) 13.9 (17) 15 (20) 15.6 (25) 14.1 (25) 15.9 (38) 14.7 (171) 




 This study described persons who died in Marion County, Indiana, from an 
opiate-related overdose between 2007 and 2014.  Death certificates, toxicology reports, 
and narratives from the DCFOR were used for data collection and analyses.  Most of the 
decedents (63.6%) were male with average age of 40 (SD=12) years.  Over 80% of these 
decedents were Caucasian and had been Marion County residents.  Over 75% of the 
decedents had a high school education or higher.  These findings are consistent with 
previously published epidemiological data from Utah, the U.S., and Canada (Johnson et 
al., 2012; King, Fraser, Boikos, Richardson, & Harper, 2014).   
Although the protocol for this research study is not the first of its kind (Andrews 
& Kinner, 2012; Cerda et al., 2013; Mueller et al., 2006; Piercefield et al., 2010; Scott et 
al., 2007), the dissemination of the methods in this manner is unique and serves a far-
reaching public health need by illustrating a strategy of using readily available public 
information to aid in combating a community epidemic.  Websites such as the CDC’s 
WONDER provides descriptive mortality trends, but they are unable to include 
toxicology reports and death investigation reports (i.e., DCFOR) that could provide more 
insight and information concerning these opioid fatalities.  If targeted and tailored 
interventions for specific populations at risk of overdose fatalities are intended to address 
the epidemic, integrating multiple sources of data is needed in order to paint a full picture 
of opiate-related overdose fatalities.  By linking the PDMP data with the coroner records 
and DCFOR information, a deeper layer of understanding of who is at risk is being 
discovered.  Additional layers can be readily added and precisely matched as identifying 
information is connected with the death certificates.  Next steps with this project can 
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incorporate local, state, and federal Department of Corrections, Medicaid information, 
and records from first responders including, fire, police, and ambulance.  One final 
notable aspect of this project concerns the feasibility of implementing such a project 
within a specific community.  All data and information were primarily collected and 




Chapter 3 Predictive Factors of Decedents Who Overdose On Heroin, Prescription 
Painkillers, or a Combination of Both 
Background 
Prescription painkiller and heroin-related overdose deaths are a national, state, 
and local public health concern (Rudd, Aleshire, Zibbell, & Gladden, 2016).  In the U.S., 
opiate overdose deaths have seen over a threefold increase from 1999 (13,995 deaths) to 
2015 (48,987 deaths) (Centers for Disease Control and Prevention [CDC], 2016).  
Indiana and Marion County (the county of the state capital and Indiana’s largest urban 
area) experienced a similar trend, but with a far greater increase between 1999 and 2015.  
Indiana reported 145 deaths related to opiate overdoses in 1999 and 1,140 deaths in 2015, 
almost an eight-fold increase (CDC, 2016).  Marion County reported 14 deaths in 1999 
and 244 deaths in 2015, over a seventeen-fold increase (CDC, 2016).  In Table 5, the 
number of deaths and the crude death rate are displayed per 100,000 people for the US, 
Indiana, and Marion County for the years 1999 – 2015.  Figure 2 is a comparative line 
graph reporting the crude death rate per 100,000 people for the US, Indiana, and Marion 
County. 
It is likely the progression of fatalities will continue to rise as the demand for 
prescription painkillers increases.  Retail sales of prescription painkiller medications in 
the U.S. have increased 149% from 1997 to 2007 and account for 80% of global 
painkiller consumption (Manchikanti, Fellows, Ailinani, & Pampati, 2010).  To some 
extent, this use of prescription painkillers has some justification, as the Institute of 
Medicine (2011) estimates 100 million U.S. adults suffer from chronic pain.  Chronic 
severe pain is prevalent in diseases, such as cancer (Deandrea, Montanari, Moja, & 
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Apolone, 2008), diabetes (Krein, Heisler, Piette, Makki, & Kerr, 2005), HIV/AIDS 
(Tsao, Stein, & Dobalian, 2010), sickle-cell disease (Elander, Lusher, Bevan, Telfer, & 
Burton, 2004), and gastro-intestinal illnesses (Bruce & Krukowski, 2006).  Specific 
populations have been identified as especially challenged by pain, such as children 
(Finley, Kristjansdottir, & Forgeron, 2010), older adults (Reisner, 2011), racially and 
ethnically diverse individuals (Anderson, Green, & Payne, 2009), military personnel and 
veterans (Kerns & Dobscha, 2009), and recently released prisoners (Andrews & Kinner, 
2012; Binswanger, Blatchford, Lindsay, & Stern, 2011; Wakeman, Bowman, McKenzie, 
Jeronimo, & Rich, 2009). 
Table 5: Opiate-related Fatalities: Number of Deaths and Crude Death Rate, 1999-2015 
Year 
United States Indiana Marion County 
# of deaths 
Death Rate 
per 100,000 # of deaths 
Death Rate 
per 100,000 # of deaths 
Death Rate 
per 100,000 
1999 13,995 5 145 2.4 14 1.6 
2000 14,572 5.2 157 2.6 11 1.3 
2001 16,170 5.7 207 3.4 19 2.1 
2002 19,829 6.9 200 3.2 14 1.6 
2003 21,732 7.5 314 5.1 15 1.7 
2004 23,599 8.1 392 6.3 22 2.5 
2005 26,219 8.9 449 7.2 20 2.3 
2006 30,525 10.2 555 8.8 34 3.9 
2007 31,915 10.6 598 9.4 58 6.6 
2008 32,655 10.7 608 9.5 58 6.5 
2009 33,379 10.9 786 12.2 137 15.2 
2010 34,898 11.3 792 12.2 132 14.6 
2011 37,982 12.2 854 13.1 144 15.8 






















Source: CDC WONDER website 
 Further exploration concerning overdose deaths involving chronic pain and 
chronic diseases or illnesses could be helpful in addressing this problem.  Research has 
not identified if one specific form of chronic pain (i.e., neurological, back pain) or 
chronic disease or illness (i.e., cancer, HIV/AIDS, diabetes) has a strong positive 
relationship with prescription painkiller overdoses.  This information could be important 
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for physicians and other health care providers in order to place a greater emphasis on 
informing their patients about the risks of overdose from prescription painkillers, as well 
as encouraging them to prescribe naloxone to their patients.   Similarly, we also do not 
know if specific populations are at risk for prescription painkiller overdoses (i.e., 
children, older adults, people from racially and ethnically diverse backgrounds).   
Figure 2: Opiate Related Crude Death Rate per 100,000 People 
 
Source: CDC Wonder website 
Similar focus on specific overdose fatalities could also be used with specific 
populations and subcultures at risk for heroin or prescription painkiller overdoses, such as 
college students, military personnel and veterans, and individuals recently released from 
jail or prison (Andrews & Kinner, 2012; Binswanger et al., 2011; Kerns & Dobscha, 
2009; Wakeman et al.,, 2009).  Some research demonstrates that although these 
populations are at risk for overdoses, specific risk profiles from within these populations 
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Perhaps, the largest gap in the literature may be the identification of the best way 
to distribute naloxone in states and cities that do not have or do not have the need for 
needle exchange programs.  Part of the problem with using needle exchange programs as 
a model for distribution is twofold.  First, if a large HIV/AIDS concern does not exist in a 
city or state, or it has been determined that the HIV/AIDS population in a city or state 
acquired their infection through other channels and not because of IDUs, needle 
exchange programs would have little practical value.  The second problem with using a 
needle exchange program model for the prevention of prescription painkiller overdoses 
assumes that people who use and misuse prescription painkillers behave and have a 
similar social network as those who use and misuse heroin.  Currently, data do not 
suggest that users and misusers of heroin behave and share social networks with users 
and misusers of prescription painkillers.  
Methods 
Research Questions. 
The purpose of this study was to conduct a longitudinal epidemiological analysis 
of opiate-related fatalities in Marion County, Indiana, using publicly available 
information.  The project aimed to:  (a) Report the types of opiates identified in blood 
toxicology reports and (b) Present the medical histories of decedents as reported in the 
Deputy Coroner Field Officer’s Reports (DCFOR).  Additional analyses were conducted 
to determine if decedent characteristics differed depending on the type of opiate fatality 
based on the toxicology report: 1) heroin alone, 2) painkillers alone, and 3) heroin and 
painkillers combined. Questions of interest included: 
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1. Are demographic variables differentially predictive among the three types of 
opiate fatalities? 
2. Are the reported individual health histories in the deputy coroner field officer 
reports differentially predictive of the three types of opiate fatalities? 
3. Is poly drug use predictive of the three types of opiate fatalities? 
Data Source. 
 Using public records from the Marion County (Indianapolis, Indiana) Coroner’s 
Office (MCCO) from 2007 to 2014, overdose fatalities due to prescription painkillers and 
heroin were identified among all recorded fatalities.   Indiana’s medical death 
investigation system is county-based, and investigations are conducted by an elected 
coroner.  State statute requires the Coroner to investigate deaths resulting from violence 
or casualty, deaths of citizens who were in apparently good health, deaths apparently 
associated with suspicious, unusual, or unnatural circumstances, and deaths of people 
who had been found dead (Ind. Code Ann. §36-2-14-6).  A manual review was conducted 
of all records with a manner of death (MOD) determined as accident, undetermined, or 
suicide.  All case subjects were deceased and toxicology reports confirmed that each 
death was caused by an opiate or an opiate contributed in the death of the individual.  
This study was designated exempt from oversight by the Indiana University IRB as this 
research did not include living human subjects. 
Measures. 
Type of opiate fatality. 
 All blood toxicology reports were reviewed to determine which opiate(s) were 
involved in the fatal overdose.  Overdoses were categorized into three groups: (1) those 
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involving only heroin, which was confirmed by the presence of only 6-
monoacetlymorphine; (2) those involving only prescription painkiller, confirmed by the 
presence of specific metabolites in the blood (i.e., hydrocodone, oxycodone, fentanyl) 
and (3) those with confirmed quantities of both heroin and painkiller metabolites in the 
blood.  A three-category outcome variable for type of opiate fatality was constructed 
where, 0 = only heroin, 1 = only painkillers, and 2 = both heroin and painkillers. 
Demographic variables. 
 Gender, age, race, education level, veteran status, Marion County residency, and 
Indianapolis residency (determined by zip code) were identified from the death 
certificates.  Gender, veteran status, Marion County residency, and Indianapolis residency 
were assigned as dichotomous variables where, 0 = male, 1 = female, 0 = no, and 1 = yes.  
After review of frequency counts, a dichotomous variable for race was assigned, where, 0 
= white and 1 = not white.  Education was assigned a four-category variable where, 0 = 
some high school education or less, 1= high school diploma or equivalency degree, 2 = 
some college, 3 = college graduate and above.  Age was not categorized and remained in 
its interval form.  These variables were used to address Research Question #1. 
Socioeconomic status indicator. 
A census-derived, standardized socioeconomic status (SES) indicator (Carlson, 
McNulty, Bellair, & Watts, 2014; Hensel, Hummer, & Tanner, 2016) was developed 
based on the percentage of people with a high school degree or higher, percentage of 
families below the poverty level, percentage of female-headed households, percentage of 
owner-occupied homes, percentage of vacant homes, and median household income.  A 
standardized value was created for each variable by generating a z-score.  Three of the 
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variables – high school degree, median income, and owner-occupied homes – were 
reverse-scored in order for lower values to reflect a lower score.  All six variables were 
then added together to create an interval score.  The lower the score, the lower the SES.  
This variable, combined with the above demographic variables, were used to address 
Research Question #1. 
Opiates. 
 The type of opiate(s) related to the fatality were determined by the toxicology 
reports and were reported by the generic names of the drugs and were categorized as 0 = 
not present and 1 = present. 
Health histories as reported in Deputy Coroner Field Officer Reports (DCFOR). 
 All DCFOR variables were reviewed for additional histories and behaviors that 
have been identified in the literature as being predictive of an overdose (King, Fraser, 
Boikos, Richardson, & Harper, 2014) (i.e., histories of acute or chronic pain, mental 
health disorders, substance misuse, injection drug use (IDU), overdoses, suicide attempts, 
and recent release from incarceration or an inpatient facility).  Further information about 
this process is detailed elsewhere (Willis et al., 2017).  In all, seven variables were 
created: (1) history of acute or chronic pain; (2) mental health history; (3) substance 
misuse history; (4) IDU history; (5) previous overdoses; (6) previous suicide attempts; 
and (7) recently released from incarceration or an inpatient setting.  All variables were 
dichotomous and measured whether a history was present or not where, 0 = no and 1 = 




 Polydrug use was defined as having another substance in the blood toxicology 
report in addition to opiates.  All variables were dichotomous and measured whether a 
substance was present or not where, 0 = no and 1 = yes.  These variables were used to 
address Research Question #3. 
Data Analysis 
All data were analyzed using SPSS 22.0 (IBM, Armonk, NY).  As the aims of this 
study were exploratory, data were analyzed using descriptive procedures, focusing on 
frequencies and percentages for key demographics such as, gender, race, Indianapolis 
residency, veteran status, and highest level of education.  Additionally, frequencies and 
percentages were reported for type of opiate found in blood toxicology reports and past 
significant histories as described in the DCFOR (e.g., an injury, disease, disorder, or 
surgery causing acute or chronic pain; a mental health history; a substance misuse 
history; IDU history; overdose history; suicide history; recent release from incarceration 
or inpatient setting).   
Due to the dependent variable being nominal with more than two levels a 
stepwise, likelihood ratio, multinomial logistic regression analysis was chosen to estimate 
a regression model that correctly predicts the probability of opiate-related overdose 
decedents having only heroin, only painkillers, or a combination of heroin and painkillers 
in their toxicology reports.  Prior to conducting the analysis, chi-square and independent 
t-tests were used to examine the bivariate relationship between each independent variable 
and the three groups of opiate-related overdose decedents.  Each of the independent 
variables (i.e., gender, mental health history, cocaine use) were entered individually into 
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a single multinomial logistic regression, twice, to identify significant relationships.  A 
multinomial logistic regression analysis was run twice to allow each of the dependent 
variables to be compared to one another, as a multinomial logistic regression analysis will 
hold one of the dependent variables as the referent group (Field, 2009).  Statistically 
significant bivariate relationships at the p ≤ 0.05 level were entered into the initial 
multinomial logistic regression (Table 9).   
Results 
Type of Opiates from 2007–2014. 
Percentages and frequencies for the various opiates involved in Marion County 
overdose deaths between the years 2007 and 2014 can be found in Table 6.  In Figure 3, 
these data illustrate the trends of opiates involved in opiate-related overdoses.  Heroin 
was identified in over a third of all the deaths (38.4%, n=451) and 
hydrocodone/hydromorphone was found in a quarter of fatalities (25.1%, n=295).  
Oxycodone/oxymorphone (20.8%, n=244) was the third most common opiate identified 
in overdose fatalities, followed by methadone (17%, n=199), fentanyl (14.1%, n=166), 
and morphine (12.7%, n=149), respectively.  Examining Figure 4, two trends are notable.  
First, heroin use appeared to fluctuate in use along with all of the other opiates from 2007 
through 2010.  However, starting in 2011 deaths due to heroin overdoses began to 
increase dramatically through 2014.   This constant trend upward is in contrast to all the 
other opiates continuing to fluctuate throughout the years.  Second, in the last year of this 
study, we see a sharp increase in identifying fentanyl in opiate-related overdoses, from 11 
occurrences in 2013 and 67 occurrences in 2014. 
  
42 
Deputy Coroner Field Officer Reports from 2007 – 2014. 
 A review of the related research literature identified several variables related to 
opiate overdoses (King et al., 2014).  Percentages and frequencies for these variables 
from the DCFOR are presented in Table 7 from 2007 through 2014.  These variables are 
illustrated in Figure 5 as trends in opiate-related overdoses.  For the entire eight years of 
this study, a total of 1174 overdose fatalities occurred in Marion County.  56.8% were 
reported to have had a previous injury, surgery, disease, or disorder that could cause 
acute or chronic pain (n=667).  30.8% were reported to have had a mental health history 
(n=362).  81.8% were reported to have a history of substance misuse (n=960).  15.3% 
were reported to have had a history of IDU (n=180).  13.3% were reported to have had at 
least one previous overdose before their fatal overdose (n=156).  7.2% were reported to 
have had at least one previous suicide attempt (n=84).  8.3 % were reported to have been 
recently released (within the past two weeks) from incarceration or an inpatient setting 
(n=97). 
Sample as Categorized into Three Groups Based on Type of Opiate. 
The study sample consisted of 1174 decedents categorized into three groups based 
on the type of opiate in their blood toxicology report.  The demographics, significant 
histories reported in the DCFOR, and poly drug use are presented in Table 8 by total 
sample and type of opiate fatality (only heroin, only painkillers, both heroin and 
painkillers).  Almost two-thirds of the decedents were male (63.6%, n=747), a large 
majority were White (85.6%, n=1005) and most lived in Marion County (82.5%, n=969).  
Almost half had a high school diploma or equivalency (47.8%, n=561) and 8.5% were 
veterans (n=100).  The average age was just under 40 years old with the youngest being 
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16 and the oldest 81 and the average value for the SES indicator, with lower the score 
indicating a lower SES, was -0.57 with the lowest value being -11.72 and the highest 
value being 7.93. 
 Over half of the sample had a reported history of an injury, illness, or surgery 
causing acute or chronic pain (56.8%, n=667).  Just under one-third were reported to have 
had a mental health history (30.8%, n=362).  The majority of decedents were reported to 
have had a substance abuse history (81.8%, n=960), whereas 15.3% (n=180) and 13.3% 
(n=156) were reported to have had a history of IDU and a previous overdose, 
respectively.  A history of a previous suicide attempt was reported for 7.2% (n=84) 
decedents and 8.3% (n=97) were reported to have been recently released from 
incarceration or an inpatient setting. 
 More than half of the decedents had a least one benzodiazepine in their blood 
toxicology reports (54.4%, n=639).  Cannabis (22.5%, n=264), alcohol (21.6%, n=254), 
and cocaine (19.2%, n=225) were the next most common substances found in the 
toxicology reports, respectively.  Amphetamines (including methamphetamine) were 






Table 6: Identified Opiates from Blood Toxicology Reports 
 2007-2014 % (n) 
 2007 2008 2009 2010 2011 2012 2013 2014 Total 
 n=84 n=122 n=130 n=123 n=137 n=160 n=178 n=240 N=1174 
Heroin 16.7% (14) 36.9% (45) 32.3% (42) 22.8% (28) 33.6% (46) 44.4% (71) 48.9% (87) 49.2% (118) 38.4% (451) 
Fentanyl 20.2% (17) 9.8% (12) 13.1% (17) 15.4% (19) 8% (11) 6.3% (10) 7.3% (13) 27.9% (67) 14.1% (166) 
Methadone  34.5% (29) 25.4% (31) 19.2% (25) 22.8% (28) 21.2% (29) 11.9% (19) 10.7% (19) 7.9% (19) 17% (199) 
Oxycodone/oxymorphone 19% (16) 20.5% (25) 22.3% (29) 26% (32) 18.2% (25) 23.1% (37) 21.9% (39) 17.1% (41) 20.8% (244) 
Hydrocodone/hydromorphone 25% (21) 17.2% (21) 36.2% (47) 31.7% (39) 28.5% (39) 30.6% (49) 23.6% (42) 15.4% (37) 25.1% (295) 
Morphine 15.5% (13) 13.9% (17) 16.9% (22) 8.1% (10) 13.9% (19) 18.8% (30) 7.9% (14) 10% (24) 12.7% (149) 
All other opiates 7.2% (6) 4.9% (6) 10% (13) 9.8% (12) 9.5% (13) 4.4% (7) 6.2% (11) 10.4% (25) 8% (93) 
Percentages may add up to over 100% and number counts could exceed the yearly number of fatalities as each fatality could have had more than one opiate identified 
in the toxicology report. 
 
Table 7: Histories and Behaviors Reported in Deputy Coroner Field Officer Reports 
 2007-2014 % (n) 
 2007 2008 2009 2010 2011 2012 2013 2014 Total 
 n=84 n=122 n=130 n=123 n=137 n=160 n=178 n=240 N=1174 
History of pain 46.4 (39) 59.8 (73) 60.8 (79) 65 (80) 56.9 (78) 60 (96) 56.7 (101) 50.4 (121) 56.8 (667) 
Mental health 28.6 (24) 31.1 (38) 30.8 (40) 37.4 (46) 30.7 (42) 26.9 (43) 27.5 (49) 33.3 (80) 30.8 (362) 
Substance misuse 67.9 (57) 81.1 (99) 76.9 (100) 69.9 (86) 79.6 (109) 83.8 (134) 86 (153) 92.5 (222) 81.8 (960) 
IDU 1.2 (1) 4.1 (5) 10 (13) 2.4 (3) 4.4 (6) 18.8 (30) 24.2 (43) 32.9 (79) 15.3 (180) 
Previous overdose(s) 8.3 (7) 12.3 (15) 10.8 (14) 17.1 (21) 18.2 (25) 8.1 (13) 14 (25) 15 (36) 13.3 (156) 
Suicide attempt(s) 8.3 (7) 8.2 (10) 8.5 (11) 13 (16) 8.8 (12) 3.8 (6) 5.1 (9) 5.4 (13) 7.2 (84) 
Recent incarceration 6 (5) 11.5 (14) 4.6 (6) 4.1 (5) 2.9 (4) 8.8 (14) 8.4 (15) 14.2 (34) 8.3 (97) 
Percentages may add up to over 100% and number counts could exceed the yearly number of reported histories and behaviors as each reported history and behavior 




















Demographics      
  Male, % (n) 63.6 (747) 77.5 (259) 55.3 (400) 75.2 (88) 0<.001 
  White, % (n) 85.6 (1005) 78.7 (263) 89.3 (646) 82.1 (96) 0<.001 
  Resident Marion Cty, % (n) 82.5 (969) 77.5 (259) 84.6 (612) 83.8 (98) 0.02 
  Education     0.006 
    Some HS, % (n) 24.1 (281) 21.8 (72) 24 (172) 31.9 (37)  
    HS Diplma/GED, % (n)  48.2 (561) 50.2 (166) 46.2 (332) 54.3 (63)  
    Some college, % (n) 14.7 (171) 16 (53) 15 (108) 8.6 (10)  
    College grad, % (n) 13 (152) 12 (40) 14.8 (106) 5.2 (6)  
  Veteran, % (n) 8.6 (100) 9.0 (30) 8.3 (60) 8.5 (10) 0.911 
  Age, mean (sd) 39.69 (12.32) 37.44 (12.03) 40.72 (12.42) 39.68 (11.73) 0<.001 
  SES, mean (sd) -0.57 (5.07) -0.60 (5.58) 0.16 (4.83) 0.76 (4.89) 0.018 
      
Reported Histories       
  Acute/chronic pain, % (n) 56.8 (667) 38.6 (129) 65.6 (474) 54.7 (64) 0<.001 
  Mental health, % (n) 30.8 (362) 17.4 (58) 38.9 (281) 19.7 (23) 0<.001 
  Substance misuse, % (n) 81.8 (960) 94.6 (316) 74.4 (538) 90.6 (106) 0<.001 
  IDU, % (n) 15.3 (180) 28.1 (94) 6.8 (49) 31.6 (37) 0<.001 
  Previous overdose, % (n) 13.3 (156) 8.7 (29) 15.6 (113) 12 (14) 0.006 
  Suicide attempt, % (n) 7.2 (84) 4.5 (15) 8.9 (64) 4.3 (5) 0.013 
  Incarceration/inpatient, % (n) 8.3 (97) 14.4 (48) 5.5 (40) 7.7 (9) 0<.001 
      
Poly Drug Use      
  Benzodiazepine, % (n) 54.4 (639) 41.6 (139) 58.9 (426) 63.2 (74) 0<.001 
  Cannabis, % (n) 22.5 (264) 24.3 (81) 20.6 (149) 29.1 (34) 0.09 
  Alcohol, % (n) 21.6 (254) 30.5 (102) 17.2 (124) 23.9 (28) 0<.001 
  Cocaine, % (n) 19.2 (225) 28.7 (96) 13.6 (98) 26.5 (31) 0<.001 
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Individual Bivariate Analysis of Independent Variables. 
 The results of the individual bivariate multinomial logistic regression analyses are 
presented in Table 9.  Of the seven demographic variables, all had a statistically 
significant relationship with the dependent variables, except for veteran status.  All seven 
factors from the DCFOR were found to have a significant relationship with the dependent 
variables, while benzodiazepine, alcohol, and cocaine had a statistically significant 
relationship with the dependent variables and cannabis and amphetamines did not have a 
statistically significant relationship. 
Table 9: Initial Multivariate, Multinomial Logistic Regression Model Results of 
Predictive Characteristics of having Either Only Heroin, Only Painkillers, or Both 
Heroin and Painkillers in Blood Toxicology Reports 
Variable χ2-value ρ value  
Age 3.87 0.144 
SES 5.80 0.055 
Gender 10.76 0.005 
Race 18.29 0<.001 
Education 11.75 0.068 
Marion County resident 0.06 0.969 
Acute/chronic pain 14.20 0.001 
Mental health 12.47 0.002 
Substance misuse 25.75 0<.001 
IDU 61.41 0<.001 
Overdose 5.85 0.054 
Suicide 1.28 0.527 
Incarceration/inpatient 6.72 0.035 
Benzodiazepine 16.63 0<.001 
Alcohol 14.36 0.001 
Cocaine 7.65 0.022 
 
Multinomial Logistic Regression Analyses. 
In all, 16 variables were found to be statistically significant and thus were entered 
into the initial multinomial logistic regression analysis: Gender, Race, Age, Education, 
Indianapolis Residency, Socioeconomic Status Indicator, Acute/Chronic Pain History, 
Mental Health History, Substance Misuse History, IDU History, Overdose History, 
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Suicide History, Incarceration History, presence of Benzodiazepines, presence of 
Cocaine, and presence of Alcohol. 
 The initial multinomial logistic regression analysis found statistically significant 
associations (at the p ≤ 0.05 level) between the three groups of opiate-related overdose 
decedents and ten variables: gender, race, acute/chronic pain history, mental health 
history, substance misuse history, IDU history, incarceration history, benzodiazepine, 
cocaine, and alcohol.  On the other hand, significant associations were not detected 
between the three groups of opiate-related overdose decedents and age, socioeconomic 
status, education, Indianapolis residency, overdose history, and suicide history (Table 9).  
Consequently, these six factors were excluded from the final predictive model (Table 10). 
See Table 10 for the Chi-square and ρ-values of the significant variables for the 
final predictive model.  Table 11 presents the odds ratios, confidence intervals, and ρ-
values for the statistically significant predictive values of having either only heroin, only 
painkillers, or both heroin and painkillers in blood toxicology reports. 
Table 10: Final Multivariate, Multinomial Logistic Regression Model Results of 
Predictive Characteristics of having Either Only Heroin, Only painkillers, or Both 
Heroin and Painkillers in Blood Toxicology Report 
Variable χ2-value ρ value  
Gender 14.23 0.001 
Race 14.01 0.001 
Acute/chronic pain 23.38 <0.001 
Mental health 14.92 0.001 
Substance misuse 27.19 <0.001 
IDU 64.12 <0.001 
Incarceration/inpatient 6.89 0.032 
Benzodiazepine 16.51 <0.001 
Alcohol 12.90 0.002 





Table 11: Odds Ratios, Confidence Intervals, and ρ-values for the Statistically Significant 
Predictive Values of having Either Only Heroin, Only Painkillers, or Both Heroin and 
Painkillers in Blood Toxicology Reports 
Characteristic 
Only Painkiller 
Versus Only Heroin 
OR (95% CI)  
Both Versus 
Only Heroin 
OR (95% CI) 
Only Painkillers Versus 
Both 
OR (95% CI) 
Demographics    
  Gender    
    Male 0.58** (0.42-0.82)  1.14 (0.68-1.92) 0.51** (0.32-0.83) 
  Race    
    White 2.08*** (1.39-3.12) 1.04 (0.59-1.84) 1.99* (1.13-3.52) 
Reported Histories     
  Acute/chronic pain 2.04*** (1.52-2.78) 2.00** (1.28-3.13) 1.01 (0.66-1.54) 
  Mental health 1.82*** (1.28-3.37) 0.94 (0.54-1.67) 1.92** (1.16-3.23) 
  Substance misuse 0.28*** (0.16-0.48) 0.47 (0.21-1.08) 0.58 (0.29-1.15) 
  IDU 0.26*** (0.17-0.40) 1.59 (0.97-2.63) 0.17*** (0.09-0.28) 
  Incarceration/inpatient 0.53** (0.32-0.87) 0.56 (0.26-1.19) 0.95 (0.43-2.08) 
Poly Drug Use    
  Benzodiazepine 1.43* (1.05-2.75) 2.50*** (1.59-4.00) 0.56** (0.36-0.88) 
  Alcohol 0.54*** (0.38-0.76) 0.85 (0.51-1.39) 0.64 (0.39-1.05) 
  Cocaine 0.63** (0.44-0.90)  1.05 (0.64-1.72) 0.60* (0.37-0.98) 
* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001 
 
Research question #1: Are demographic variables differentially predictive among the 
three types of opiate fatalities? 
 Decedents had lower odds of being male (OR = 0.58, 95% CI = 0.42-0.82) and 
higher odds of being white (OR = 2.08, 95% CI = 1.39-3.12) when found to have only 
painkillers in their blood versus those with only heroin.  Decedents were found not to be 
statistically significantly different in gender or race with both heroin and painkillers in 
their blood versus those with only heroin.  Decedents had lower odds of being male (OR 
= 0.51, 95% CI = 0.32-0.83) and higher odds of being white (OR = 1.99, 95% CI = 1.13-




Research question #2: Are the reported individual health histories in the deputy 
coroner field officer reports differentially predictive of the three types of opiate 
fatalities? 
Decedents had lower odds of substance misuse history (OR = 0.28, 95% CI = 
0.16-0.48), history of IDU (OR = 0.26, 95% CI = 0.17-0.40), and recent release from 
incarceration or an inpatient setting (OR = 0.53, 95% CI = 0.32-0.87), but greater odds of 
a reported history of acute/chronic pain (OR = 2.04, 95% CI = 1.52-2.78) and mental 
health history (OR = 1.82, 95% CI = 1.28-3.37) when found to have only painkillers in 
their blood versus those with only heroin.  Decedents had greater odds of a reported 
history of an injury, illness, or surgery causing acute or chronic pain (OR = 2.00, 95% CI 
= 1.28-3.13) when found with both heroin and painkillers in their blood versus those with 
only heroin.  Decedents had lower odds of having a reported history of IDU (OR = 0.17, 
95% CI = 0.09-0.28), but had greater odds of a reported mental health history (OR = 
1.92, 95% CI = 1.16-3.23) when found with only painkillers in their blood versus those 
with both heroin and painkillers. 
Research question #3: Is poly drug use predictive of the three types of opiate fatalities? 
Decedents had lower odds to have had cocaine (OR = 0.63, 95% CI = 0.44-0.9) 
and alcohol (OR = 0.54 95% CI = 0.38-0.76) in their blood, but had greater odds of 
having benzodiazepines (OR = 1.43, 95% CI = 1.05-2.75) in their blood when found to 
have only painkillers in their blood versus those with only heroin.  Decedents had greater 
odds of having benzodiazepines (OR = 2.50, 95% CI = 1.59-4.00) in their blood with 
both heroin and painkillers in their blood versus those with only heroin.  Decedents had 
lower odds of having benzodiazepines (OR = 0.56, 95% CI = 0.36-0.88) and cocaine (OR 
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= 0.60, 95% CI = 0.37-0.98) in their blood with only painkillers in their blood versus 
those with both heroin and painkillers. 
Discussion  
The types of opiates found in the toxicology reports of this study are similar to 
other cities and states (Cerdá et al., 2013; Piercefield, Archer, Kemp, & Mallonee, 2010; 
Shah, Lathrop, Reichard, & Landon, 2007).  It is unclear why some painkillers are found 
in high frequencies some years and not in others, while some painkillers appear to have a 
fairly stable rate of use.  Explanations for this observation include cost, prescribing 
habits, and availability of each specific opiate painkiller.  A much more nuanced 
examination using provider and PDMP data is needed to understand this use of 
prescription painkillers. 
When looking at the reported histories from the DCFOR, a few findings warrant 
further discussion.  First, over half of the decedents in the analysis were reported to have 
had a history of some type of accident, surgery, illness, disorder, or disease that could 
cause acute or chronic pain.  Additionally, almost one-third of the decedents were 
reported to have had a mental health disorder.  According to the USDUH the US 
prevalence for any type of mental health disorder is about 18.5%.  Thus, it would appear 
that a disproportionate number of individuals with a previous mental health history died 
in Marion County from opiate-related overdoses.  Moreover, the annual average of 
individuals who were reported to have had a mental health history for each year in this 
study hovered around the overall average of 31% (range 26.9-37.4%).  The averages for 
individual years did not vary much from the overall average.  This observation is 
important, because the increase in opiate fatalities that has been occurring in Marion 
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County from 2007-2014 cannot be explained by or attributed to mental health.  If mental 
health was a contributing factor to this increase, we should see an increase in the 
proportion of people who were reported to have had a mental health history.  This finding 
further supports the notion that we are dealing with a problem that affects multiple people 
and multiple cultures.  Ultimately, the narratives provided in the DCFOR suggests that 
many of the decedents were suffering and in some type of physical and/or emotional 
pain. 
When looking specifically at those decedents with only painkillers in their 
toxicology report compared to those with only heroin, we find statistically significant 
differences on all variables used in the multivariate, multinomial logistic regression.  This 
is important to understand because the people who use painkillers are much different 
from those who use heroin and this can influence prevention and intervention strategies.  
Decedents with only heroin in their toxicology report were more likely to be male and 
white.  When comparing their reported histories, decedents with only heroin in their 
toxicology reports were more likely to have a substance misuse and IDU history and 
more likely to have been recently released from incarceration or an inpatient setting.  
Expanding on the substance misuse history, decedents with only heroin in their 
toxicology reports were more likely to have had alcohol and cocaine metabolites present 
in their toxicology report.  These findings are similar to findings from an Australian study 
of recently released inmates who died of accidental drug-related causes.  Those 
individuals were significantly less likely to have had a mental health history and 




 In the present study, decedents with only painkillers in their blood versus 
decedents with only heroin in their blood present a different story.  These decedents are 
more likely to be female, to have had a history of acute or chronic pain, and to have had a 
mental health history.  One interesting finding concerning the mental health history is that 
these decedents were more likely to have had benzodiazepines in their blood, which 
supports the increased likelihood of their reported mental health history being accurate.  
Additionally, this co-occurring use of prescription painkillers and benzodiazepines 
reinforces the conventional wisdom that the use of prescription painkillers and 
prescription medicine in general is not thought of as misusing substances, which offers an 
explanation for the large odds ratio of decedents with only heroin in their toxicology 
report being more likely to have had a substance misuse history.   
 The many differences found between decedents with only heroin compared to 
decedents with only painkillers in their toxicology reports is not observed when 
comparing decedents with both heroin and painkillers in their blood versus decedents 
with only heroin in their blood.  In fact, only two variables were statistically significantly 
different – history of acute or chronic pain and presence of benzodiazepine in the blood.  
Decedents with both heroin and painkillers in their blood were more likely to have had a 
reported history of acute or chronic pain and more likely to have had benzodiazepine in 
their blood.  Further investigation is needed to fully understand these results, but the 
history of acute or chronic pain could suggest these decedents were using prescription 
painkillers at one time to treat their pain, which may have led to eventual misuse of 
painkillers and initiation of heroin use. 
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 When comparing decedents with only painkillers in their toxicology reports 
versus those with both painkillers and heroin in their blood results are quite similar to the 
results found when comparing decedents with only painkillers in their blood to those with 
heroin in their blood.  Decedents with only painkillers in their blood versus those with 
both heroin and painkillers were more likely to be female, White, and to have no IDU 
history.  Additionally, decedents with painkillers in their blood were more likely to have 
a mental health history and to have no cocaine metabolites in their blood.  Results 
indicate that those with painkillers in their blood compared to those with both heroin and 
painkillers were not different with respect to histories of acute or chronic pain, substance 
misuse, and recent release incarceration or inpatient setting.  The major difference when 
comparing the different groups (i.e., only painkillers vs. only heroin and only painkillers 
vs. both heroin and painkillers) concerns benzodiazepines being present in the blood.  
Decedents with only painkillers in their blood versus those with both heroin and 
painkillers were less likely to have benzodiazepines in their blood.  In contrast, decedents 
with only painkillers in their blood were more likely to have benzodiazepines in their 
blood than those with only heroin.  As with some of the other results, this finding needs 
further exploration in order to understand how it may inform prevention and intervention 
strategies.  Concerning the targeting of specific groups for provision of naloxone, the 
results of this study suggest people with a history of acute or chronic pain and a mental 
health history are at risk of dying from an opiate-related overdose.  Furthermore, 
individuals who are prescribed or known to misuse benzodiazepines should be informed 
of their increased risk of dying from an opiate-related overdose and should be given a 
prescription to and instructed on the use of naloxone. 
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A concerning finding from this study is the large increase in IDU, especially 
during the last three years of the analysis.  These findings are even more alarming when 
considered in context with the recent HIV/AIDS outbreak that occurred in Scott County, 
Indiana, which was largely driven by IDU and needle sharing.  Along with concerns of 
spreading HIV/AIDS, increases in hepatitis C infections have been found among both 
injection users and non-injection users.  Moreover, Bruneau and colleagues (2012) 
observed increased likelihood of seroconversion among those who inject only 
prescription painkillers opposed to those who inject both heroin and prescription 
painkillers. 
Ultimately, all of these deaths were preventable.  Clinical and policy responses 
aimed at addressing the misuse of prescription painkillers typically offer opiate specific 
treatment centers, increased enforcement, implementation of prescription drug 
monitoring programs (PDMP) (Gugelmann & Perrone, 2011), and reduction in 
prescribing opioids (Dowell, Haegerich, & Chou, 2016).  Although PDMPs can decrease 
the amount of diverted prescription drugs in the community, they have had limited 
success with decreasing use of prescription drugs and have little to no effect on the 
number of overdose mortalities (Paulozzi, Kilbourne, & Desai, 2011).  Additionally, 
recent evidence reports the decline in opiates being prescribed by physicians, however, 
opioid-related overdose fatality rates continue to rise (Schuchat, Houry, & Guy, Jr., 
2017).  
As a result, an alternative approach proposed to respond to overdose mortalities 
involves a more fluid dissemination of an opiate antidote, naloxone.  Naloxone is an 
opiate antagonist that safely and effectively reverses the often-fatal respiratory depression 
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effects caused by an opiate overdose (Chamberlain & Klein, 1994; Sporer, 2003).  
Naloxone only works with opiates and has no similar antidote properties for any other 
illicit or licit drug, including alcohol (Chamberlain & Klein, 1994; Sporer, 2003) and has 
been clinically available since 1962 (Baselt, 2000).  Naloxone has been routinely used by 
paramedics, emergency departments, and other medical services to reverse the otherwise 
fatal effects of a heroin or prescription painkiller overdose (Sporer, 2003; Strang, 
Kelleher, Best, Mayet, & Manning, 2006).  Despite its extensive clinical history and 
efficacious nature, it is relatively unknown to the general community and has limited use 
due to federal and state administrative restrictions (Beletsky, Burris, & Kral, 2009; 
Burris, Norland, & Edlin, 2001; Davis, Webb, & Burris, 2013; Green et al., 2013). 
Naloxone is needed tremendously throughout the U.S and a strong push to 
increase naloxone access is coming from multiple fronts (legal, medical, and policy 
scholars) focusing on three targeted areas.  The first targeted area is to increase the 
number of physicians who are prescribing naloxone.  Primary care physicians and other 
physicians who have more frequent contact with active opiate users, such as ED 
physicians, are encouraged to provide naloxone prescriptions to their patients that are 
active opiate users (Beletsky et al., 2006; Kim, Irwin, & Khoshnood, 2009; Sporer & 
Kral, 2007).  Additionally, chronic pain physicians and other physicians who work 
closely with people with painful chronic illnesses, such as cancer, are also being asked to 
provide naloxone prescriptions, due to the increased risk of chronic pain patients 
misusing their prescription painkillers (Beletsky et al., 2009; Beletsky, Rich, & Walley, 
2012).  Unintentional overdoses are more likely to involve prescribed medication than 
illicit drugs (CDC, 2012).   
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The second targeted area is to advocate for changes in state laws and regulations 
that restrict the availability of naloxone.  As described above, only eight states have taken 
direct measures to address the legal, civil, and medical liability that may follow 
administering naloxone.  Some states have passed laws that allow other licensed medical 
professionals (i.e., nurse practitioners, physician assistants) to prescribe naloxone, instead 
of only a physician (Beletsky et al, 2009; Burris et al., 2009).   
Finally, the third targeted area involves the Food and Drug Administration (FDA) 
reclassifying naloxone from prescription-only to an over-the-counter (OTC) drug.   This 
process can be lengthy, cumbersome, and expensive, due to all of the paperwork and 
filings required of pharmaceutical companies.  However, support is strong for this option  
as the best way to make naloxone readily available  (Beletsky et al., 2009; Burris et al., 
2009; Coffin et al., 2003; Compton, Volkow, Throckmorton, & Lurie, 2013; Kim et al., 
2009; Lagu et al., 2006; Seal et al., 2003; Sporer & Kral, 2007). 
Limitations 
 This study has several limitations.  First, the results inform us only about the 
individuals who died in Marion County, Indiana and whose deaths were investigated by 
the MCCO.  It is likely that some people whose deaths were opiate-related were never 
investigated by MCCO for a variety of reasons.  For example, if a physician listed the 
cause of death as natural and caused by cancer there would be no need for an 
investigation and toxicology report.  Similarly, hospital administrative error could release 
a deceased individual to a mortician before final steps were enacted to notify MCCO of 
the death.   
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Second, as a retrospective study, the internal validity could be negatively affected 
due to the data being collected for archival reasons and not specifically for this study.  
Third, the results inform us only about the individuals who died and thus we are unable to 
define fully who is at greatest risk of a fatal overdose.   
Fourth, we were unable to identify opiates by specific trade names due to the 
chemical structure of the opiates and how they are metabolized in the body.  All drugs 
from the Marion County toxicology reports are reported by generic name.  For example, 
Vicodin and Percacet (trade names) each contain hydrocodone.  Toxicology tests detect 
hydrocodone, for example, but do not determine which brand of hydrocodone was taken.  
Additionally, hydrocodone is metabolized to hydromorphone.  Hydromorphone will 
remain in the blood stream long after the hydrocodone has been completely metabolized.  
Thus, the toxicology assay can be interpreted as showing the presence of an opiate, but 
we cannot then know if it was hydrocodone or hydromorphone.  The same is true for 
oxycodone, which is likewise metabolized to oxymorphone.  Because Vicodin and all 
other hydrocodone-containing medications metabolize to hydromorphone, which is itself 
a painkiller and the main ingredient of Dilaudid and Opana, it is not possible to tell from 
the results of toxicological assays which specific drug was taken.  Opana is significant to 
this study because a common way to misuse this drug is to inject it, and Opana was 
identified as a significant variable in the recent HIV/AIDS outbreak that occurred in Scott 
County, Indiana.   
A fifth limitation of the study involves important independent variables of this 
study – the reported histories as detailed in the DCFOR.  There are layers to this 
limitation that introduce bias and error into the analysis.  First, all of this information is 
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second-hand at best and cannot be verified.  Additionally, the Deputy Coroner Field 
Officer determines individually what sources and information are to be included in the 
DCFOR.  Some information may not be determined to be pertinent to the investigation 
and is excluded from the DCFOR.  Finally, there is not one Deputy Coroner Field Officer 
investigating and writing the reports and like any occupation there is turnover and 
attrition for this position.  Human error, inexperience, and personal styles and preferences 
can all impact how a DCFOR is written. 
The social work implications of this analysis are far-reaching.  Understanding this 
information is important on many levels, with implications for education, policy, clinical 
practice, and research.  The results of this study suggest that teaching BSW and MSW 
students about the risk of overdose fatalities from the misuse of prescription painkillers 
and heroin is something that should occur in general social work classes and not just in 
substance misuse curricula, as the population affected by this problem reaches far beyond 
people who misuse substances, to family, friends, and community.  Social work policy 
actions could include informing legislators and policy makers about the devastating 
effects of overdose fatalities and the need to create laws and regulations that improve the 
distribution and availability of naloxone, an antidote for opiate overdoses.  Implications 
for clinical social work include educating social workers on identifying those at risk of an 
overdose, and advocating for naloxone to be prescribed or otherwise made available to 
those who are at risk of an overdose and to their families and friends.  Finally, social 
work research needs to focus on further understanding this epidemic and, using 
community data, such as that from correction and judicial programs, Medicaid, and 
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prescription drug monitoring programs, to further understand and predict those who are at 






Chapter 4 Conclusion 
People as young as 16 and as old as 81 years old died from an opiate-related 
overdose in Marion County, Indiana between the years 2007-2014.  Some of these people 
had a lifelong history of substance misuse.  Some had an extensive medical history with 
frequent hospitalizations.  Some people were recently released from incarceration, some 
from an inpatient hospital stay, and some recently completed inpatient substance misuse 
treatment.  Some of these people had significant mental illnesses, some previously 
overdosed on a prescription painkiller or heroin, and some have a history of using needles 
to inject drugs. 
The three papers in this dissertation describe the process of using publically 
accessible local data to better understand a developing public health concern.  The first 
paper described the methods used to identify, gather, and collect the information needed 
to create a database for analytical purposes.  The second paper was a descriptive paper 
that reported the demographics of the decedents, the type of opioids found in toxicology 
reports, and the reported medical and behavioral histories of the decedents.  The final 
paper explored the predictive characteristics of decedents who overdosed on heroin, 
prescription painkillers, or a combination of both. 
This study demonstrated that people who have died from an opiate-related 
overdose in Marion County are more heterogeneous than homogeneous, however, the one 
commonality that all of these people share is that their death was preventable and their 
access to an antidote for their overdose was severely limited by policies and regulations.  
This was a social injustice and as a social worker it is my ethical duty to seek out and 
rectify social injustices.   
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 The results from this study further highlight social injustices and expand the 
discussions concerning society’s awareness and treatment of mental illness, physical 
pain, inmates, ex-offenders, and people in recovery from substance misuse and other 
issues.  All levels of human development and systems of behavior are effected and 
influences how social workers will work with adolescents, young adults, older adults, 
couples, families, and even larger social networks and communities.  Social work 
education, practice, policy, and research are all affected by the misuse of prescription 
painkillers and heroin.  The impact, scope, and harm of misuse of prescription painkillers 
and heroin has transcended being just an addiction concern and has now become an issue 
that is touching all aspects of society. 
 The purpose of this project was to determine if the availability and reach of 
naloxone can be increased by directly identifying and targeting specific groups of people 
most at risk for an overdose fatality in Marion County, Indiana.  More specifically, could 
the same sources of data (death certificate, autopsy and coroner’s reports, and toxicology 
reports) that were used to inform us of the developing overdose epidemic be used to 
inform doctors, nurses, and others with prescribing authority on the type of patient or 
situation where a naloxone prescription would be warranted due to the high likelihood of 
an overdose?  Currently, I am unable to determine if this study was able to answer the 
purpose and specific aim of the dissertation as my design was not prospective, however, 
the evidence is strong enough to warrant increased advocacy and discussion expanding 
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Appendix A. List of Injury, Surgery, or Other Potential Pain Causing Condition 
 
2007 
 knee surgery 
 Chronic pain/2Back Sur 
 Guillain-Barre syndrome 
 degenerative back disease 
 broken ankle 
 hysterectomy 
 head/neck cancer/surgery/back-knee 
surgery 
 back pain/neck fracture 
 shoulder/disc dislocation 
 chronic back pain 
 GSW-abdomen 
 Parkinson's 
 MVA-back problems/kidney stones 
 back surgery 
 migraine/knee replacement 
 chronic back pain 
 hysterectomy/GI tube/intestinal 
obstruction/ovarian cysts 
 knee pain 
 back pain 
 GSW-chest 
 knee surgery/colonoscopy 
 bariatric surgery 7 years ago 
 breast cancer/surgeries/hysterectomy 
 broken back-metal plate/pins in thumb 
 gastric-bypass 6 years ago 
 disc surgery on back 
 kidney stones/neck surgery/MVA 
 back problems 
 disk replacement 
 MVA-back problems/kidney stones 
 malignant hystosynosis 
 back problems 
 MS 






 numerous hip surgeries/degenerative 
disk disease/chronic pain 
 
2008 
 leg/gall bladder removal 
 diabetes/foot/back pain 
 back pain 
 appendectomy 
 Hep C 
 knee surgery/extensive scrips 
 Chrons disease 
 IDDM/chronic back pain 
 HTN/OA/Hip fx/neuropathy 
 MVA-elbow surgeries 
 DM/COPD/fibromyalgia/neck and back 
pain 
 CAD w/MIx2/COPD/NIDDM/Diabetes 
neuropathy/nephritis 
 hip replacement/back surgery/dental 
extraction/chronic pain 
 Hep C/cirrhosis 
 hip dislocation 
 chronic pain 
 non-insulin diabetes 
 insulin dependent/pancreatitis 
 HIV+ 
 3 surgeries for herniated disks 
 kidney problems 
 Hep C/COPD 
 epilepsy 
 spleen injury 
 Hep C 
 Hep C/back injury/seizures 
 HIV+ 
 Hep C 
 pinched nerve in back 
 back pain 
 chronic back pain 
 hx liver/kidney failure 
 back pain/bilateral knee replacement 
 MVA 




 dental work 
 Diabetes/hysterectomy/cyst removed 
from face 
 Bowel resection/hypothyroidism 
 Hep C 
 chronic back/neck 
pain/seizures/Diabetes 
 Diabetes/sig med hx 





 removal of one kidney 
 chronic back pain 
 severe back pain 
 insulin dependent/dental work 
 GSW-abdomen 
 surgical scar on ankle 
 gastric bypass (15 years 
ago)/hysterectomy/severe arthritis 
 Chronic pain/OA 
 sickle cell 
 Diabetes/GSW-scrotum/HIV+ 
 Hep C 
 chronic back pain 
 chronic pain/hysterectomy/neck 
surgery/gall bladder 
removed/migraines/degenerative disk 
 deviated septum surgery 
 heart problems 
 gastric bypass (9-10 years ago)/3-4 
surgeries to correct problems-2008 most 
recent/hernia/rheumatoid arthritis 
 Diabetes 
 leg/knee pain 
 chronic pain 
 diabetes/MRSA 
 back pain/liver/heart disease 
 diabetes 
 back pain/hip pain/diabetes/sleep apnea 
 seizures 
 Hep C/Diabetes/Cirrhosis/hernia 
 Chronic pain/HTN 




 healing fracture of tibia/extensive 
medications 
 diabetes 
 serious MVA 2 years ago w/multiple 
fractures 
 partial hysterectomy 
 total hysterectomy/left thyroidectomy 
 gastric bypass/hernia repair 
 gunshot wound causing paraplegic 
 total hysterectomy/cholecystectomy/left 
hip surgery 
 chronic back pain from 2 MVA 
 cardiac surgery 
 mitral valve prolapse/scrips 
 arthritis/anemia 
 MVA-broken neck/spine fracture/tumor 
in brain/c-section/CAH 
 heart surgery 
 Hep C/Congestive Heart Failure 
 c-section/ovarian cysts 
 chronic back pain 
 scoliosis 
 GSW-shoot in stomach in Iraq 




 Hep C/on disability due to back and 
legs 
 neck surgery/appendectomy 
 fibromyalgia/irritable bowel 
syndrome/sleep apnea/hysterectomy 
 neck injury from MVA 
 fibromyalgia/chronic pain/nerve 
damage in jaw/fractured 
shoulder/surgical scar on ankle 
 bilateral mastectomy/cholecystectomy 
 appendectomy 
 3 herniated discs/breast reduction 
surgery 
 numerous surgical scars on both arms 
and hands/2 surgical scars on 
legs/surgical scar on butt/diabetes 
 surgical scar on ankle 
 rheumatoid arthritis/Lupus 
 tubal ligation/HIV+ 
 quadruple bypass/nerofibrosyis 
 seizures 
 AIDS/pancreatitis/shingles 
 fibromyalgia/cracked rib 
 cirrhosis/Hep C 
 fibromyalgia 
 stage 4 lung cancer 
 colostomy/AIDS 






 gastric bypass/hernia surgery 
 surgical scar on pelvic 
region/hysterectomy 
 cholecystectomy/appendectomy/diabete
s/MVA leading to bi lateral knee 
replacement/chronic pain 
 back surgery 2-3 years ago 
  
80 




 lung cancer/appendectomy 
 surgical scar on knee/HTN 
 surgical scar on hand 
 cholecystectomy 
 diabetes 
 disc problems/carpal 
tunnel/diabetes/pain 
 chronic back pain/HTN 
 paraplegic/shot 5xs/severely beaten on 
head needing surgeries and metal 
plates/spleen & gall bladder removed 
 fractured collarbone/hep c 
 bariatric surgery/cholecystectomy 
 HTN/appendectomy 
 kidney stones/ulcers/neurologist for 
headaches 
 2 separate surgical scars on abdomen 
and pelvis/HTN 
 hysterectomy/MIs/CVAs 
 kidney transplant 3/2009 
 orchiectomy/surgical scars on 
abdomen/neck and shoulder injuries 
 chronic pain syndrome/partial right 
mastectomy/left iliac crest 
surgery/surgery of lumbar spine/kidney 
stones/cancer/neurovasculitis/copd 
 gsw to chest/tibia fracture/HTN/surgical 
scars on chest and arm 
 HTN 







ctomy/colonoscopy/false teeth fitting 
 surgical scar on chest 
 appendectomy 
 appendectomy 
 fractured shoulder/boxer fracture of 
finger/osteoarthritis 
 CAD/COPD/dementia/diabetes/CVA/TI




 bariatric surgery/appendectomy 
 chronic back pain 
 
2010 
 Hep C/rape victim 
 end stage emphysema(COPD)/lung 
mass/HBP 
 COPD/pancreatitis 
 chronic pain since 13/hip 
replacements/chemo 
 recent stent surgery/HBP/diabetes/MS 
 brain surgery 
 hysterectomy 
 herniated discs/fibromyalgia 
 gall bladder removal 
 Prostate cancer/Hep C 
 Chronic foot pain/diabetes/nerve 
damage 
 chronic pain/osteoporosis 
 fibromyalgia/shoulder surgery/liver & 
spleen problems 
 pancreatitis/asthma/COPD 
 back problems/spine stimulator 
 appendectomy 
 broken back/surgical scar on abdomen 
 stroke/back and hip pain 
 congestive heart failure 
 bariatric surgery - 2004/surgery 3/23/10 
 chronic pain/fibromyalgia 
 knee surgery 2009/hbp 
 MVA/back problems/rods & pins in 
legs/asthma 
 hemorrhoid surgery/nonhodgkin 
lymphoma 
 kidney stones 
 cyst removed from back and tailbone 
 back pain/seizures 
 rotator cuff surgery/kidney stones 
 ovarian cancer/HBP 
 back, knee, leg, foot 
pain/fibromyalgia/HBP 
 recent critical car accident 
 Hep C 
 back injury 





 old back injury 
 severe leg pain/hypothyroid 
 Hep C 
 back surgery/seizure 
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 kidney transplant/Elport 
syndrome/osteoporosis/20 years dialysis 
 amputation of toes/diabetes/diabetic 
ulcers/kidney cancer 
 leg injury 
 cancer 
 injured knee 
 thyroid cancer-removal/broken foot 
 broken thumb 
 healed surgical scar 
 HIV+ 





 Chron's/chronic back pain/IBS 
 surgical scars on abdomen 
 Chron's/extensive other surgeries-
problems 
 several medical problems 
 Seizures/HTN/COPD 
 MVA/chronic pain 
 spinal degeneration/chronic back 
pain/Lumbar Spondylosis/toe 
amputation/bunionectomy 
 heart stents 
 leg pain 
 chronic back pain 
 back injury 
 bariatric surgery/degenerative disk 
disease/sleep apnea 
 back surgery 
 appendectomy 
 sleep apnea 
 Vulva cancer/GSW 
 diabetes/lower back pain/kidney stones 
 surgical scars on abdomen 
 diabetic 
 Hep C/cancer 
 Colon cancer 
 appendectomy 
 surgical scars on abdomen 
 2 neck surgeries/spinal problems 
 fibromyalgia/partial 
hysterectomy/cervical cancer 







 numerous back surgeries 
 shoulder problems/gall stone surgery 
 surgical scar on hand and wrist 
 bypass-stent surgery/multiple vascular 
surgeries 
 scoliosis/titanium rods in back 
 hysterectomy/neck and shoulder pain 
 back and leg pain/diabetes 
 gastric bypass-1996/migraines/constant 
pain 
 lupus/surgical scar on neck 
 recent assault ruptured spleen 
 back pain 
 brain surgery/seizures/hep c 
 hysterectomy/bilateral salpingo-
oophorectomy 
 chronic back pain/pancreatitis/hep c 
 recent victim of robbery - broken nose, 
ribs, and numerous bruises contusions 
throughout/HIV+ 
 Pineal tumor in brain 
 recent compressed disc 
 surgeries for boils on back 
 appendectomy 
 heart valve replacement 
 gout/chronic pain 
 hysterectomy 
 hysterectomy 
 fibromyalgia/something else in/out of 
hospitals since age 14 
 serious heart problems 
 hit by car 
yesterday/cholecystectomy/hysterectom
y/bilateral salpingo-oophorectomy 
 cystic fibrosis/pancreatitis/9.5" of colon 
removed when 12 
 back pain 
 hysterectomy/cholecystectomy/ovarian 
cyst removal 
 breast implants 
 hysterectomy 
 back disease 
 plate in head due to bar fight 
 chronic pain due to MVA/gout 
 abdominal surgery/bariatric 
 degenerative disc disease/back knee 
pain/copd/emphysema/arthritis 
 c-section/chronic back pain 
 amputated big toe/throat cancer 
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 lymphoma/chronic back pain 
 kidney problems/pinched nerve in 
shoulder 
 multiple back surgeries/chronic pain 






 fell off bike 2 weeks ago and fractured 
ribs 
 cosmetic surgeries-tummy tuck, breast 
implants/cholecystectomy\ 
 abdominal surgery 
 quadruple bypass 
 sleep apnea 
 exploratory laparotomy 
 bowel surgery after rupture during 
birth/diabetes/MS/Chrons disease 
 hysterectomy/kidney stones/back pain 
 degenerative disc disease/stomach 
pain/bad knees 
 cholecystectomy/icepick headaches 
 chronic back pain/wrist surgery 
 chronic back pain/polycystic kidney 
 surgical scar on neck/exploratory 
laparotomy/surgical scar on ankle 
 cystic fibrosis 
 neuropathy/fibromyalgia 
 severe back pain 
 chronic pain/motorcycle accident - 
breaking clavicle/fell from garage roof 
 back surgery/gout/deviated septum 
surgery 
 kidney stones 
 hysterectomy/bilateral saphinogo-
oophorectomy 
 surgical scars on both feet and ankles 
 severe neuropathy 
 Fibromyalgia/rheumatoid arthritis 
 chronic pain/gout/diabetes 
 sciatica/appendectomy/lumbar stenosis 
 brain aneurysm surgery 
 dirt bike accident/MVA-alcohol related 




 AIDS/surgical abdomen scars 
 chronic back pain/spinal 
defects/testicular cancer 
 appendectomy/hernia repair/chronic 
pain from MVA - broken neck 
 back pain 
 recent outpatient surgery/partial 
hysterectomy 
 bariatric surgery 2 years ago 
 2 back surgeries 
 
2012 
 AIDS/TB/Hep C 
 Fibromyalgia/Degenerative spine 
disease/hip pain/surgical scar on right 
hip 
 disc problems 
 carpal tunnel surgery and bone marrow 
biopsy on 1/9/12/chronic pain/surgical 
scars on other hand 
 back pain/multiple MVAs 
 diabetes 
 Chron's Disease 
 hospitalized for 31 days 12/2011 for 
falling off bridge and breaking leg 
 diabetes 
 terminal thymus cancer 
 kidney stones/Bell's palsy 
 back injury/surgical scar on right 
shoulder 
 partial foot amputation 
12/2011/diabetes/Guillians-Barre 
 chronic back pain/scoliosis/disc 
herniation/laparoscopic 
cholecystectomy 
 back pain 
 surgical scar on chin 
 chronic knee pain after 
replacements/chronic hip pain/3 c-
section births/deviated septum surgery 
 ruptured ovarian cyst on 3/16/12 
 GSW/forklift accident 
 diabetes 
 diabetes 
 MVA w/neck injury 2010 
 hysterectomy/appendectomy/chronic 
back pain/multiple surgeries 
 fibromyalgia/spinal 
degeneration/surgical scar on arm 
 surgical scar on wrist 
 back pain 
 knee surgery due to 12/2011 MVA 




 acute pancreatitis/back pain/surgical 
scar on back/cholecystectomy 
 HIV+/paralysis waist down/beaten 
up/13" surgical scar on 
abdomen/surgical scars on both arms 
 hysterectomy 
 double leg amputation 
 diabetes/arthritis/pain 
 chronic back pain/fibromyalgia 







 surgical scrotal procedure 
 diabetes 
 recent extraction of top 
teeth/cholecystectomy 
 diabetes/open heart surgery/valve 
replacements 
 diabetes/back pain from MVA 
 diabetes/14 teeth pulled on 
6/27/2012/surgical scar on abdomen 
 sickle cell/nasal polyps surgery 
yesterday 
 lupus 
 gout/exploratory surgery/shot in 
abdomen 6 years ago 
 chronic back pain/nerve pain 
 total hysterectomy/cholecystectomy 
 intracranial surgery/tubal 
ligation/MS/leukemia/breast cancer 
 diabetes/kidney tumor/gout/chronic 
pain syndrome/stent placement 
 gastric bypass in 
2009/arthritis/cholecystectomy 
 stent placement/diabetes 
 spinal meningitis/seizures 
 19 pins in foot due to job accident over 
a year ago 
 Grand Mal seizures/sees a neurologist 
 appendectomy 
 valve replacement/splenectomy/stent 
placement 
 partial hysterectomy/ovarian 
cysts/cholecystectomy 
 stomach bleeds 
 hysterectomy/back and neck surgeries 
for herniated discs 
 cancer/ulcers/arthritis 
 chronic pancreatitis 
 kidney stones 
 back and neck pain/splenectomy/hernia 
repair/joint replacement 
 surgical scar on elbow/ALS 
 splenectomy/pancreatitis/hernia 
repair/diabetes 
 back pain/cyst removed off 
tailbone/growth on spine/sacral ulcer 
with wound vacuum and antibiotic 
therapy 
 cholecystectomy 
 pancreatic problems 
 surgical scar on hip/seizures 
 hernia repair/seizures 
 shot in face 11/2011 
 diabetes/seizures/dialysis/surgical scar 
along left costal margin 
 lymph node cancer & chemo 
 disabled from motorcycle accident 
 foot injury 
 bad knees/appendectomy/tubes tied 
 osteoarthritis/injections in spine for pain 
management 
 back problems 
 surgery for arthritis in ankle 
 pelvic injury/lost left eye from bb gun 
 chronic pain 
 sutured scar on wrist 




 boxer-fracture of hand 
 lumbar surgery/tubal ligation/gallstones 
 chronic head pain 
 partial hysterectomy 
 diabetes/kidney injury 
 back injury on disability 
 laparoscopy/R&L knee 
repair/hysterectomy/cholecystectomy/m
ultiple sinus surgeries/4 MVAs, last one 
lifelined 
 appendectomy/severe headaches 
 diabetes/abdominal surgical 
scar/surgical scar on knee 
 
2013 
 recently broken arm 
 chronic back pain 





 chronic arthritis 
 motorcycle accident 
 diabetes 
 scoliosis/chronic back and joint pain 
 cystic 
fibrosis/diabetes/appendectomy/placem
ent of gastrostomy tube 
 cholecystectomy 
 cholecystectomy 
 staples on fallopian 
tubes/fibromyalgia/chronic pain 
 bariatric surgery, 10 years 
ago/hysterectomy/appendectomy/cholec
ystectomy/osteoporosis-2 broken ankles 
in past year, multiple leg fractures 
 diabetes 
 neck pain 
 hernia surgery 
 kidney tumor 
 pancreatitis-stent placement 
 tooth extraction 
 chronic pain from 38ft scaffolding 
fall/hep c 
 neuropathy/cholecystectomy 
 gsw to abdomen 
 spine surgery/diabetes 
 chronic back pain 




 gsw-parapelgic, multiple operations 
 constant pain 




 chronic pain/surgical scar on ankle 
 diabetes/cholecystectomy/tubal ligation 
 previous rib fracture 





 surgical scar/endoscopy/colonoscopy 
 hernia surgery 
 cholecystectomy 
 fibromyalgia/cholecystectomy/arthritis/
back and stomach pain 
 2 purple hearts 
 caesarean section 




 open heart surgery/both knees needing 
replacement 
 back pain 




 surgical scar on knee 
 tubal ligation/diabetes/broken 
ankle/bursitis 
 fractured nose from MVA 
 back surgery/both shoulders replaced 
 multiple back surgeries/diabetes/chronic 
pain 
 severe injury to right arm/constant acute 
pain 
 cholecystectomy 
 fibromyalgia/back pain/gall 
stones/diabetes 
 hysterectomy/appendectomy 
 partial leg 
amputation/MS/seizures/chronic pain 
 hysterectomy/cholecystectomy/abdomin
al wall reconstruction/chronic back pain 
 arthritis/extreme pain in shoulder and 
hip 
 rod placed in femur after MVA/diabetes 
 lung cancer 
 hernia surgery 
 breast implants/tummy tuck 
 appendectomy 
 surgical scar on abdomen 
 chronic back and leg pain 
 degenerative disc disease/chronic back 
pain/cholecystectomy 




 fibromyalgia/2 back surgeries/fractured 
hand 
 bulging disc/back pain from 
MVA/surgical scar on arm 
 partial foot amputation/chronic pain 
 lost both legs in Vietnam/chronic back 
pain/glaucoma 





 tubal ligation/cholecystectomy/4 
laparoscopies/left ankle surgery 
 appendectomy 
 back and neck pain/cholecystectomy 
 cholecystectomy 
 2 falls from ladders in 7/2013 resulting 
in broken ribs and 5 days in hospital 
 torn ligament in leg/broken hand 
 hysterectomy/kidney stones/multiple 
surgeries for kidney problems 
 bypass graft surgery 
 hip replacement 
 appendectomy 
 pacemaker 
 surgical scar on leg 
 prostate cancer 
 pelvic surgery/three surgical scars on 
ankles and calf 
 lung cancer 
 liver transplant/degenerative disc 
disease/cholecystectomy 
 diabetes/arthritis 
 bleeding ulcers requiring surgical 
procedure 
 spinal injury while spelunking/constant 
pain 
 back fusion 
surgery/diabetes/neuropathy/back pain 
 diabetes 
 MVA serious head trauma 
 MVA in 2010 leading to right lower 
paralysis/Grave's disease 




 gastric bypass/cholecystectomy/chronic 
back pain 
 cholecystectomy/partial hysterectomy 
 
2014 
 leg injury/back pain/bowel 
problems/headaches/cholecystectomy 
 occasional back pain 
 ulcers 
 chronic pain/COPD/HTN 
 removal of cyst in tail region/Hep C/GI 
bleeds 
 foot surgery last 
year/cholecystectomy/diabetes/arthritis 
 recent surgery on leg that was the last of 
three/epilepsy 
 chronic pancreatitis, multiple surgeries 
to both knees, non-Hodgkins lymphoma 
 ovarian cancer, hysterectomy 
 left thalamic deep brain stimulator 
placement-1/10/14/pacemaker 
 diabetes 
 heart transplant, 2007/gastroparesis last 
6 weeks 
 Fibromyalgia/diabetes/8" surgical scar 
on chest/surgical scar on wrist/surgical 
scar on abdomen 
 severe migraines since age 12 




 chronic back pain 
 chronic pain from 2006 MVA involving 
surgeries/tubal ligation 
 Hep C 
 Fibromyalgia/scoliosis/epilepsy/surgical 
scars on fallopian tubes 
 degenerative disc disease/hep c/GERD 
 hep c 
 fell out of tree a week ago, hospitalized 
for 3 days/surgical staples 
present/broken ribs 
 stabbed on 2 separate occasions one 
time collapsed lung 
 cholecystectomy 




 fibromyalgia/bone cancer in jaw 
 degenerative disc 
disease/diabetes/COPD/multiple 
surgical scars on body 
 bypass surgery/ASHD 
 hear stent/diabetes 
 chronic back and spine 
pain/copd/emphysema 
 hemorrhoid surgery 
 Hep C 
 hep a,b,c/abdominal hernia/CHF 
 recent cholecystectomy (open 
scar)/chronic osteo arthritis/COPD 
 diabetes/trach due to excessive 







 shoulder and back pain/seizures 
 seizures 
 cholecystectomy 
 HIV/AIDS/Hep B/renal failure/CHF 
 chronic back pain/back and hip surgery 
 gastric bypass/hernia/hysterectomy with 
bilateral salpingo-oophorectomy 
 MS/diabetes/GERD/COPD/emphysema
/spinal fusion with chronic back pain 
 Back 
pain/emphysema/COPD/cholecystecto
my/hysterectomy with bilateral 
salpingo-oophorectomy 
 leg pain/assault 
 crushed ankles in fall 
 diabetes 
 non-Hodgkin's lymphoma/chemo and 
radiation/adhesions to chest wall with 
chronic pain 
 fx left wrist in bicycle accident 





surgery/mandible surgery/web neck 
 bilateral tube 
ligation/arthritis/tonsillectomy 
 broken arm last month/seizures 
 degenerative disc 
disease/diabetes/COPD/emphysema/2 
neck surgeries 
 triple bypass/hep c/diabetes 
 metallic staples (uterovesical pouch of 
Meiring)/bilateral fallopian tube scars 
 numerous surgical scars on legs and 
abdomen 
 surgery on rt. arm caused by injection 
 open heart 
surgery/copd/cad/diabetes/hep c/uterine 
cancer/hysterectomy/seizures/chf 
 injuries from 1/2014 car accident/1/2 
colon removed 
 chronic headaches - treated with vicodin 
 stent placement 
 diabetes 
 spleen, thyroid, pancreas with benign 
tumors - removed or resected/multiple 
endocrine neoplasia/diabetes/open heart 
surgery 
 car accident 
 renal failure-dialysis/diabetes 
 surgical scars on legs and abdomen 
 diabetes/arthritis 
 appendectomy 
 motorcycle accident shattering left 
foot/chronic pain/recent hydrocodone 
scrip for bronchitis 
 tonsillectomy 
 open heart surgery/pacemaker/valve 
replacement 
 broken wrist from snowboarding 
 degenerative disc disease/left shoulder 
surgery/arthritis/COPD 
 AIDS/colon cancer 
 chronic back pain/spondylosis 
 back pain/foot problems 
 stent placement 
 back injury 
 pain in side of head/stomach 
ulcers/mass in stomach 
 car accident 2/2014 causing chronic 
back pain 
 skin cancer 
 chronic pain 
 COPD 
 MVA/back pain 
 appendectomy 
 diabetes/hip surgery 
 recent removal of teeth 
 seizures 




 motorcycle accident, skull fx with steel 
plate/shoulder fx 
 low back and knee 
pain/COPD/emphysema 
 motorcycle accident year ago w/serious 
injuries 
 diabetes 
 COPD/chronic pain in knees 
 MVA 4 years ago fractured neck 
 irritable bowel 
 appendectomy 
 stent placement 
 recent burn on hand requiring skin graft 
 MVA 2 weeks ago-fractured hip, ribs, 
facial injuries 
 Hep c 
 bariatric surgery/4 cosmetic 
surgeries/breast implants 




 chronic pain 
 seizures from head trauma from sexual 
assault 
 hep c 
 fibromyalgia 
 diabetes/emphysema/COPD 
 GSW to left side/chronic knee pain 
 Liver stents/cirrhosis/chf 
 2 hip replacements/seizures/migraines 
 bilateral tubal ligation/cholecystectomy 
 frequent falls/multiple blood 
transfusions/Cirrhosis 
 GSW to leg/COPD/Cancer right lung 
 migraines 
 assault causing head trauma, loss of left 
eye sight, taste, and smell/seizures 
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